Rooibos tea flavonoids increase mineral content in human osteoblast-like cells by Nash, Leslie Alanna
  
 
 
 
 
 
 
Rooibos tea flavonoids increase mineral content in human osteoblast-like cells 
 
 
 
 
Leslie A. Nash, B.Sc. (Honors) 
      
Health Sciences 
Submitted in partial fulfillment of the requirements for the degree of 
Master of Science in Applied Health Sciences (Health Sciences) 
 
Under the supervision of Wendy Ward, PhD 
 
Faculty of Applied Health Sciences, Brock University  
St. Catharines, ON 
 
© 2014 
i 
 
ii 
 
Abstract 
Some cross-sectional and prospective studies have demonstrated a positive correlation 
between habitual tea consumption and bone mineral density in post-menopausal women. 
Rooibos tea contains no caffeine and is a rich source of flavonoids such as rutin, orientin, 
hyperoside and luteolin. These flavonoids have similar structures to estradiol, and 
therefore may act as estrogen mimics to promote favourable outcomes in bone. The 
overall objective of this research was to identify flavonoids that could enhance mineral 
content in human osteoblast Saos2 cells. Mineral was quantified by alizarin red staining 
and characterized by quantifying alkaline phosphatase (ALP) activity, cell mitochondria 
activity and toxicity, in addition to changes in regulatory markers of osteoblastic activity. 
Rutin (≥50µM), hyperoside (≥5.0µM), orientin (0.1µM-1.0µM, 15µM-100 µM) and 
luteolin (5.0µM) enhanced mineral content. This was in part due to elevated ALP and 
mitochondrial activity, and lower toxicity, pro-inflammatory cytokines, and Wnt 
inhibitors. 
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Chapter 1.0 - Introduction 
 
The population of the developed world is aging. With an aging population, 
strategies for preventing chronic disease are essential for preserving quality of life and 
reducing health care costs. The aging “baby-boomer” generation in North America 
currently has an average age of 65 years, and thus is at high risk of developing chronic 
diseases. Osteoporosis is described by an individual having low bone mineral density 
(BMD) and weakened bone structure, thereby making the individual‟s skeleton more 
prone to fragility fractures [1]. According to the International Osteoporosis Foundation, 1 
in 5 men and 1 in 3 women will experience a fragility fracture within their lifetime [2]. 
Moreover, fragility fractures worldwide are frequent, occurring every 3 seconds [3]. 
Fragility fractures are more commonly seen in areas of impact such as the wrist, spine 
and hip. Fragility fractures often result in disfigurement, impaired mobility and loss of 
independence, that together result in an overall diminished quality of life [1]. Moreover, 
mortality rates are positively associated with all types of osteoporotic fractures, with the 
highest risk among men and women age 60-69 years [4,5]. Within a year of the first hip 
fracture, likelihood of death increases by approximately 30% for women and 40% for 
men [1]. The economic costs of treating fragility fractures and rehabilitation are 
substantive and a significant burden to the economy. Visits to the hospital due to 
osteoporotic fractures, occur more often than stroke, heart attack, and breast cancer 
combined [1]. Approximately 20 billion dollars a year are spent on osteoporotic related 
injuries within Canada [1] and the United States [6], and is expected to increase with the 
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aging population. Thus, there is a need to develop strategies that prevent degradation of 
bone tissue during aging, thereby preventing debilitating fractures.  
Until recently, measurements of BMD at the spine and/or hip using dual energy x-
ray absorptiometry were solely utilized to assess the risk of fragility fracture for an 
individual [1]. This measurement of BMD is described in terms of a T-score, in which the 
T score refers to how many standard deviations the BMD of the patient is from the BMD 
of the average, healthy individual. A score of -1.0 and higher is considered healthy; 
where -1.0 to -2.5 standard deviations away describes osteopenia and -2.5 or lower 
indicates osteoporosis [1]. All of the studies referenced in this thesis that measured risk of 
fragility fracture in humans (without measuring incidence of fracture directly) used BMD 
measures. However, it is important to note that clinicians are being encouraged to use the 
Fracture Risk Assessment tool (FRAX) to more accurately predict risk for osteoporotic 
fracture [7]. This assessment includes BMD as well as numerous risk factors including 
age, body mass index, medication history (i.e. previous fragility fractures, family history) 
and alcohol consumption [7]. Using these risk factors, FRAX provides an estimate of the 
10-year risk of an osteoporotic fracture. There are many different pharmacological agents 
that are used to attenuate loss of bone mass. These include bisphosphonates, a 
monoclonal antibody that binds RANKL, and selective estrogen modulators. As is 
common for most drugs, there can be adverse effects. This provides a basis for 
considering potential dietary strategies that may provide a safe approach to maintain bone 
health or delay the age at which a pharmacological agent is warranted to prevent a 
fragility fracture [7,8].  
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1.1 Overview of Drug Treatment Strategies for Osteoporosis  
 
Patients that are at low or moderate risk of fragility fracture are placed on a 
supplement regime of vitamin D, and calcium, while also being encouraged to start a 
regular exercise cycle [7]. There are a variety of drug treatments offered to assist with 
slowing bone loss in individuals who are at high risk for an osteoporotic fracture. As with 
most drug interventions, potential adverse effects can occur [7]. Bisphosphonates such as 
Fosamax and Aclasta are used to prevent bone resorption through inhibition of osteoclast 
activity. Bisphosphonates are a common treatment for osteoporosis treatment as they are 
easily accessible, and can be given either orally or intravenously. Oral medication is 
given for individuals at high risk but otherwise healthy, where intravenous injections are 
used to stabilize osteoporotic patients.  Bisphosphonates have the ability to bind to 
osteoclasts and prevent their catabolic action. This allows for osteoblasts to achieve a 
higher level of efficiency, bringing bone turnover back to a more steady state, lowering 
the risk of fracture [9].  Adverse side effects due to bisphosphonates depend on the route 
of administration. These adverse effects include muscle and bone pain, ulcers, and 
esophageal cancer. Long-term effects of bisphosphonates are currently not understood 
and therefore are only recommended for short-term usage.  
Selective estrogen modulators (SERMs), such as raloxifene, mimic estrogen 
through structure recognition. SERMs will bind to specific estrogen receptors (typically 
either alpha or beta estrogen receptors within a localized area) found within the bone. By 
binding to these receptors, they exert biological effects, similar to estrogen, and regulate 
target genes. This selectivity allows for interaction and up-regulation of genes by the 
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desired receptors while blocking these same effects within other tissues such as those 
found in the breast and uterus. However, complications such as blood clots, cancer and 
leg cramps have been associated with the use of SERMs [10].  
An alternative option for treatment is hormone therapy, in which estrogen or 
progesterone can be administered to supplement the loss of estrogen after menopause 
[10]. The Women‟s Health Initiative has shown that estrogen supplementation for 
treatment of osteoporosis can decrease risk (~30%) in overall fracture, but due to health 
risks outweighing the benefits, the study ended early. It was through the Women‟s Health 
Initiative that the use of the steroidal hormone, estrogen, was discovered to increase a 
woman‟s risk for cardiovascular disease and stroke, in addition to a variety of cancers in 
the breast and endometrium tissues [11].  
Additional hormone supplements include calcitonin and parathyroid hormones. 
Calcitonin is produced in the body naturally and is able to slow down osteoclasts, thereby 
increasing productivity of osteoblasts, and ultimately slowing bone resorption [12]. 
Recently, parathyroid hormone has shown success with upsetting the balance of 
osteoclasts to osteoblasts. This hormone works by increasing the rate of bone formation 
relative to destruction, thereby increasing BMD in areas across the body, resulting in a 
lower risk of fracture; unfortunately it is not covered in drug plans [13]. These hormone 
therapies are an effective way to slow down bone loss, preventing spine and hip fractures, 
but come with many risks such as cancer, blood clotting, elevated blood-calcium levels 
and kidney stones [1].  
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A newer pharmacological intervention is Prolia, an antibody that has been 
engineered to slow osteoclast activity by preventing the interaction of the RANK-
RANKL bond. As the RANK-RANKL bond is required for osteoclast maturation, its 
inhibition allows for depletion in osteoclast activity. Although new, the human 
monoclonal antibody is currently being pushed as a treatment to allow for „drug 
vacations‟ from osteoporosis medications in which long term effects have not been 
studied, such as bisphosphonates [12,14,15].   
With all of the above treatments, there is currently no ideal strategy to effectively 
target osteoporosis, or prevent it. Therefore it is desirable to seek a natural, efficient 
means for deterring bone loss in which side effects are few or none. This leads scientists 
to seek potential therapeutics in nature that may prove to be proficient in their ability to 
treat or prevent osteoporosis, but also abundant and potentially less expensive, making it 
a more accessible treatment.  
1.2  Bone Metabolism 
While osteoporosis is recognized to be a disease that comes with aging, bone 
health is a life-long process. Throughout the life cycle, bones are consistently remodeling 
and are influenced by a variety of factors including genetics, nutrition and physical 
activity [1]. From infancy, our bones grow and reshape until adulthood when an 
imbalance of bone production and breakdown erupts due to a loss of estrogen during 
menopause [16]. Although estrogen is commonly recognized for its ability to provide 
women with secondary sex characteristics such as breasts, males also produce estrogen. 
Males develop estrogen through an enzymatic process in which testosterone is 
synthesized into estrogen through an enzyme known as p450 aromatase. This enzyme is 
6 
 
distributed across the body, but exists largely in the brain and in adipose tissue [17]. Men 
also experience a drop in testosterone levels as they age, but it is not as dramatic as 
females whom experience menopause [17,18].   
Bone is a multifaceted tissue, largely made of mineral and matrix, while also 
containing smaller amounts of water and lipids [19]. Bone mineral, specifically 
hydroxyapatite is a semi-soluble complex composed of mainly calcium and phosphate 
[19]. The ability to solubilize hydroxyapatite via osteoclast action is appropriate to allow 
for bone turnover to maintain strong bones. To produce mineral, concentrations of 
phosphate and calcium will accumulate inside of vesicles within the bone matrix [19]. 
These extracellular vesicles provide the suitable environment for micronutrients (i.e. 
magnesium, and selenium) to ensure crystallization takes place. As phosphate and 
calcium begin to crystalize, the newly formed mineral will deposit in holes between the 
matrix, acting like cement [19]. Mineral gives the bone properties such as strength and 
hardness, where the matrix allows for the bones to be flexible and elastic. Maturation of 
matrix and mineral is typically marked by an increase in gene expression for: ALP, 
osteocalcin and osteopontin (OPN), bone sialoproteins, and non-collagen proteins, all of 
which are important to maintaining healthy bones [19]. 
7 
 
 
Figure 1.1 Bone Turnover. There are three main cell types which influence bone 
turnover; osteoblasts, cells that make bone; osteoclasts, cells that break down bone; 
osteocytes, mature osteoblasts buried in the bone matrix which are used to communicate 
between osteoclasts and osteoblasts.   
Bone turnover, the process of remodeling bone, is acknowledged as the difference 
in action of bone making cells, osteoblasts, in comparison to the activity of bone breaking 
cells, osteoclasts (Figure 1.1). Maintaining a healthy rate of bone turnover involves a 
balance of osteoblast and osteoclast activity [16]. Osteoblasts are derived from 
mesenchymal stem cells that respond to growth factors and proteins, to stimulate their 
conversion to pre-osteoblast cells. Osteoblasts are not only important for producing bone, 
but for also providing the receptor activator of nuclear factor κβ (NFκβ) ligand 
(RANKL). RANKL is responsible for binding to the RANK receptor on progenitor 
osteoclasts [20]. This interaction will promote the differentiation of progenitor osteoclasts 
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into mature osteoclasts. During this phase, macrophage colony stimulating factor (M-
CFS) will be released to signal for osteoclast differentiation and recruitment [20]. Once 
mature, osteoclasts may bind to the matrix of the bone and release hydrochloric acid 
(HCl) and proteases that activate bone resorption, a process that can be ongoing for 
several weeks [21]. Osteoblasts are also capable of releasing a ligand known as 
osteoprotegerin (OPG) that blocks the RANKL binding site to prevent osteoclast 
maturation. After osteoblasts have produced mineral, a portion of these will become 
osteocytes in the bone matrix. Osteocytes serve to communicate between osteoblasts and 
osteoclasts to instruct bone development [22].  
One of the main components of hydroxyapatite is calcium. Thus, ensuring an 
appropriate, regular intake of calcium is very important for obtaining and maintaining 
healthy bones. Currently, the daily recommended intake for calcium for adults is 1000mg 
and this further increases to 1200mg for women over the age of 50 [23,24]. There are 
plenty of food sources that supply the body with calcium such as milk, cheese, yogurt (1 
serving of dairy is approximately 300mg of calcium), and chickpeas. In addition, many 
store bought juices are fortified with calcium. Women often find it difficult to achieve the 
recommended daily intake of calcium through food and therefore are many women are 
suggested to take supplements. Calcium found within supplements is poorly absorbed 
into the body, and is therefore recommended to be taken with vitamin D. Vitamin D will 
increase absorption of calcium, enhancing calcium‟s bioavailability [19]. Vitamin D can 
also stimulate ALP, an enzyme that will produce free phosphate for the manufacture of 
bone mineral, as well as promote the differentiation of osteoblasts. Vitamin D has also 
been shown to increase gene expression of osteocalcin and osteonectin bone matrix 
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proteins, which are important for bone growth, while controlling proliferation and cell 
death of osteoclasts and cytokines [19]. When vitamin D is ingested, a more useful form, 
25-hydroxyvitamin D is synthesized by the liver, and this undergoes further modification 
in the kidneys to produce a very reactive species, 1,25-dihydroxyvitamin D. 1,25-
hydroxyvitamin D has an incredibly short half-life (4-6hrs) making it incapable to be 
appropriately measured and therefore 25-hydroxyvitamin D (stable for approximately 3 
weeks) is quantified to assess the vitamin D status of an individual [25]. Stabilization of 
vitamin D within the body takes approximately 3 months to occur. Therefore, to ensure 
an individual is consuming enough calcium and absorbing it into the body, healthy adults 
are recommended to intake a minimum of 600IU daily [23]. 
Food components other than calcium and vitamin D, can also be used to 
positively modulate bone physiology. In particular, flavonoids have been shown to have a 
positive influence on bone physiology. Flavonoids, in which their structures resemble 
estradiol, are desirable due to the potential of binding to estrogen receptors to exert 
biological effects. Furthermore, flavonoids have anti-oxidant potential, which help limit 
inflammation.  Inflammation is known to negatively affect bone turnover by increasing 
osteoclast differentiation, activity, and decreasing osteoblast activity [26]. High levels of 
reactive oxygen species have been positively associated with pro-inflammatory cytokines 
and bone resorption [27]. Therefore, flavonoids offer multiple modes of action to help 
improve outcomes in bone metabolism.  
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1.3 Estradiol, Flavonoids and Osteoporosis 
 
Estradiol (Figure 1.2) has been recognized as a key modulator for bone 
development throughout the lifecycle. Estradiol can limit cellular death of osteoblasts and 
prevent osteoclast proliferation [28]. In vitro experiments have demonstrated the addition 
of estradiol results in a significant increase in OPG levels [29], type 1 collagen and TGF-
B [30], all of which are important for suppressing osteoclast activity and building 
mineral. Estradiol directly added to human osteoblasts also results in a reduction in pro-
inflammatory markers IL1, IL6 and TNFα [31]. Pro-inflammatory markers increase 
osteoclast activity relative to osteoblast activity. However, when estradiol was added to 
human osteoblasts (1pM – 10pM), there was no significant increase in osteoblast 
proliferation or ALP [32]. In contrast, estradiol (10nM) added to Saos2 cells, resulted 
elevated nodule formation and ALP activity [33]. Therefore estradiol‟s benefits seem to 
stem from interacting with multiple pathways to help stimulate mineralization in 
osteoblasts, while indirectly suppressing the activity of osteoclasts.  
When a substrate, such as a hormone binds to an estrogen receptor, the two will 
form a complex that results in a change in shape. This new complex will give access for 
binding of response elements using its activator protein 1 (AP1) site. Binding of the 
estrogen response elements allow for recruitment of proteins that may activate or repress 
the promoter region to influence gene expression [34]. It has been demonstrated that 
mutations within genes that express estrogen receptors and enzymes such as aromatase 
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(allowing for production of estrogen from testosterone) have led to low BMD, and 
skeletal problems [35,36]. Estrogen is also a key player in the immune system where it 
can regulate inflammation through a reduction of cytokine levels. Activation of cytokines 
has been shown to influence and increase levels of osteoclasts [37]. This reduction in 
cytokine concentration helps limit inflammation, and further reduce the likelihood of 
osteoclasts upsetting the balance of osteoclasts to osteoblasts. Therefore, this loss of 
estrogen creates an increased rate of bone loss; creating fracture thresholds that exist 
earlier in life [38].   
a) OH
OH
CH3
A C
                     b)           
OOH
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Figure 1.2. Structure of a) estradiol. b) a general backbone of a flavonoid.  
Rings A and C of estrogen and the general backbone of a flavonoid are similar. R 
represents different chemical moieties that can be added to the structure where R‟ 
represents additional functional groups within subclasses  
Flavonoids such as epigallocatechin gallate (EGCG) from green tea have been 
shown to increase mineral deposition by increasing the activity of ALP [39]. Lycopene, a 
flavonoid found in a variety of fruits such as tomatoes is recognized to be a powerful 
antioxidant and has shown the ability to increase osteoblast activity and mineral 
deposition at micromolar concentrations [40]. Naringin, a flavonoid found in high 
concentrations in oranges was shown to increase tibia bone strength and BMD when 
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ovariectomized rats consumed the flavonoid over a period of 6 weeks [41]. Rooibos tea is 
a rich source of flavonoids that may have effects on bone health. Therefore, this thesis 
will specifically study four flavonoids present in rooibos tea: rutin, orientin, luteolin, and 
hyperoside to test their ability to modulate mineral deposition in bone cells.    
Tea, as well as many fruits and vegetables contain polycyclic systems known as 
flavonoids. These flavonoids represent a class of chemical compounds with multiple 
rings that are responsible for adding taste, smell and color to food and beverages. These 
compounds can be further broken down into classes such as: flavones, flavonols, 
flavanones, isoflavones, catechins, anthocyanidins and chalones, which are all dependent 
on the functional groups that surround their ring systems [42]. Flavonoids have become 
increasingly important because of their structural similarity to hormones such as estrogen. 
For example, part of the structure of estradiol is seen within the flavonoid rings A and C, 
and these are important for maintaining the structural properties that allow for ligand 
recognition by the estrogen receptors. (Figure 1.2). Similarities such as these allow 
flavonoids to act as substrates and produce interactions with hormone receptors that may 
result in a biological response [42].  
1.4 Tea 
Only next to water, tea is considered the beverage of choice across the world. Tea 
represents a world-wide multi-billion dollar industry. Consumption of tea has increased 
more than 10% over the past 10 years and continues to rise [43]. In 2012, there were over 
79 billion servings of tea consumed in the United States, resulting in sales of over $2.25 
billion dollars [43]. Tea, being made with numerous types of natural fruits and plants, is a 
rich source of flavonoids that are recognized for having antioxidant, antibacterial, and 
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antifungal activity [44-54]. Moreover, many, but not all, population studies are beginning 
to suggest that regular tea intake is linked to individuals with higher BMD (Table 1.1) 
than non-consumers. Also, there are a few studies that have also identified individuals 
with regular tea consumption had a reduced rate of fragility fracture than non-consumers 
(Table 1.2).  
1.4.1 Cross-Sectional and Prospective Studies: Tea and BMD 
 
 Cross sectional and prospective studies have provided substantial data suggesting 
that tea is able to impact bone health (Summary in Table 1.1) in a variety of populations. 
Studies have been conducted in North America, Europe, Australia, and Asia. 
Postmenopausal women have been most thoroughly studied with a few studies also 
including men and/or premenopausal women.  
1.4.1.1 Cross Sectional Studies 
 
A small study of 62 postmenopausal women in Canada measured BMD at the 
femur and spine. Analysis found a positive correlation between tea intake and BMD at 
both measured sites [45]. In England, BMD was measured in over a thousand post-
menopausal women at several areas in the spine and femur [46]. Women who consumed 
tea had approximately 5% greater BMD measurements at the spine, greater trochanter 
and Ward‟s triangle. In addition to this, tea consumers were categorized on whether they 
consumed their tea with milk, as milk provides a good source of calcium, which aids in 
bone development. When BMD was compared between tea drinkers who use milk to 
those who did not, no statistical difference in BMD was noted, suggesting the small 
quantity of milk added to tea does not influence BMD. They also determined that those 
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who drank 1-3 cups versus more than 4 cups a day did not influence BMD. The 
differences in BMD (i.e. 5%) translate to a 10-20% lower risk of obtaining a fracture 
[46]. These results were also reflected in a cross-sectional study completed in Japan in 
which they investigated lumbar spine BMD in Japanese women over 60 and found that 
those who consumed green tea had higher BMD and better T-scores (-1.59  2.70 versus 
-2.17  2.08) than those who did not consume tea [47]. 
A study in Iran assessed both males and females between the ages of 20-76 and 
compared the relationship between the BMD of those who consumed tea and coffee and   
non-consumers. Habitual consumption of tea was considered to be more than 5 cups/day. 
Urine and plasma were analyzed for bone markers, while BMD was assessed at the spine 
and hip. Only women whom habitually consumed tea showed a lower frequency of 
osteoporosis (5.6% versus 12.1%) and osteopenia (24.5% versus 36.5%) as (rates of 
osteoporosis were determined by the Iranian Multicenter Osteoporosis study) compared 
to non-consumers. Significance was lost when assessing the male population. This trend 
was also seen in BMD measurements, in which women who habitually consumed tea in 
general had higher BMD at the spine, but was not shown to be significant. However 
BMD at the hip was significantly higher in these women, but again lost when assessing 
the male population [48]. Similar to the Iranian females, peri-menopausal women from 
the Danish Osteoporosis Prevention Study discovered a positive correlation existed 
between the BMD in the femur and the quantity of tea consumed a day [49]. 
In contrast to the studies above in which a positive correlation existed between 
women‟s intake of tea and their BMD, Greek men ages 18-30 in the armed forces had 
their diets analyzed and compared to their bone mineral content and BMD. Bone mineral 
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content and BMD were measured at two sites, the distal and ultradistal radius. No 
relationship with identified between tea consumption and BMC or BMD [50]. Assessing 
an older population of males ages 45-65 and characterizing them by their body types, no 
significance was identified between the intake of tea and BMD at the lumbar spine and 
femur [51]. This suggests that flavonoids in the tea may have an estrogenic effect, 
producing biological effects similar to that of estrogen, which could play a role in helping 
women to slow bone loss after menopause. 
1.4.1.2 Prospective Studies 
 
A prospective study followed 1027 women for 5 years and investigated their 
BMD in relation to their intake of tea using a food frequency questionnaire. The results 
showed that hip BMD was 2.8% higher in those who consumed tea compared to those 
who did not. Moreover, 164 of these women were followed for an additional 4 years in 
which bone loss was measured. Those who drank tea experienced an average loss of 
approximately 1.6% of their total BMD at the hip over the four years, whereas non-tea 
consumers lost approximately 4.0% [52]. This suggests that tea could provide a natural 
approach to slowing attenuate bone loss. 
A study in Taiwan enrolled both males and females from the prospective survey 
of chronic disease in Tainan, to evaluate the relationship concerning customary tea 
consumption and BMD. Individuals who consumed tea once a week for a minimum of 6 
months were deemed customary tea consumers. These tea consumers were then 
categorized by years of consumption.  A positive, linear correlation was identified 
between consumption of tea and BMD for body, lumbar spine, hip neck and Ward 
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triangle. Individuals who consumed tea for +10 years had the highest levels of BMD 
amongst the groups. Individuals who consumed tea for longer than 6 years had 
significantly greater lumbar spine BMD than non-tea consumers. No significance was 
found between consumers and non-consumers when tea was consumed for less than 5 
years, suggesting benefits may only be observed with longer-term consumption [53].  
In comparison, a study done on Turkish postmenopausal women (n = 724) looked 
at population characteristics both at baseline and compared them a year later for 
osteoporosis and fracture. Groups included habitual consumers of tea, defined as +2 
cups/day, while anything less classified the individual as a non-consumer. T-scores were 
determined by measuring BMD at three different phalanges and estimated for whole 
body. Habitual consumption of tea led to women with better T-scores (-1.51 1.68 versus 
-1.09  1.66), but this was not statistically significant. Osteoporosis prevalence was also 
lower in those who consumed tea regularly (29.1% versus 37.8%) but again, this was not 
statistically significant [54].  
Positive outcomes in bone, as the result of habitual consumption of tea, are 
primarily seen in peri-menopausal women, in which women are beginning to lose (or 
already have lost) the ability to produce estrogen. Estrogen as mentioned above is 
important for building and maintaining strong, healthy bones and therefore it is likely that 
tea contains compounds that can mimic estrogen and influence estrogen receptors in a 
positive manner. Tea contains a high concentration of flavonoids, and due to the positive 
association between tea and bone health (see Table 1.1 and 1.2), women ages 45-54 had 
their BMD analyzed (lumbar spine and femoral neck) and their diet assessed for their 
flavonoid intake to identify if there was any association between flavonoid intake and 
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BMD.  The diet analysis found that 57% of flavonoid intake was attributed to 
consumption of tea, in which there was an average intake of 596504mL of tea/day. 
Furthermore, as the concentration of flavonoid increased in their system, so did BMD at 
the femoral neck and lumbar spine. Urine analysis also demonstrated that free 
deoxypyridinoline, an indicator of bone resorption was negatively correlated to flavonoid 
concentration. Overall, a negative correlation existed concerning flavonoid level and 
level of bone resorption. This recent data suggests that populations who consistently 
consume tea will have higher levels of flavonoids that may help lower bone turnover and 
sustain BMD [55].  
1.4.1.3 Prospective Studies: Tea and Fracture 
 
While BMD is a good measure of bone health, it does not tell the full story. 
Measuring the rate of fracture is important for determining how strong bones are, as the 
strength of bones can be determined by both the mineral content and the architecture. 
Ideally, fracture would be measured, as it is the fracture that makes osteoporosis most 
lethal and debilitating.  
In the United States, the Women‟s Health Initiative found a positive connection 
between tea consumption and BMD at specific skeletal sites. Fractures were reported by 
participants on an annual basis by questionnaires, and included only confirmed hip 
fractures by medical records. Other fractures were included but only as self-report. 
Measurements for BMD included total body BMD, total hip BMD and posterior-anterior 
spine BMD. Herbal and decaffeinated tea was not included for tea consumption. Unlike 
the previous study, post-menopausal women were categorized by their habitual 
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consumption of tea. Individuals who drank ≥4 cups/day had greater total body BMD and 
total body BMD in comparison to the individuals who consumed less than 1 cup/day. 
Furthermore, a positive trend was identified for how much tea was consumed and BMD. 
Women consuming between 2-3 cups a day had higher spine BMD in comparison to 
individuals who drank less than 1 cup. Although drinking tea was positively associated 
with BMD, no association was found between quantity of tea consumed, as measured by 
cups, and the rate of fracture [56].  
Findings from Women‟s Health Initiative were supported by findings from a 
study completed in Sweden. The Swedish population is recognized for their large 
consumption of caffeine, and black tea holds one of the largest concentrations of caffeine 
in tea. A longitudinal study examined the risk of bone fracture in women aged 40-76 
years over 10 years and how fracture relates to their intake of black tea and coffee. 
Fractures were identified by personal hospital records and included if they were 
considered typical areas of osteoporotic fractures such as the femur, hip, spine, distal 
forearm, pelvis and proximal humerus. Tea was separated into the number of servings 
consumed and compared against the rate of fractures. Although greater coffee ingestion 
was linked to higher bone fracture, this significance was not found with an increased 
intake of caffeinated tea [57].   
Unlike the study in Sweden, a cross-sectional study in India which paired 100 
individuals (43 male and 57 female) with fractures and compared them to a control group 
found that tea consumption increased the risk of fracture [58]. However, it is noted that 
the study included individuals of all ages and therefore may suggest that the benefits of 
tea may be only seen during midlife. Another study conducted on a Chinese centurion 
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population in which all participants were over 90 years of age, no relationship was 
identified between tea intake and osteoporotic fractures in either gender [59]. 
In contrast to the previous fracture studies, the MEDOS study, a prospective study 
completed in Europe involving six countries, measured the incidence of hip fracture in 
both genders over the age of 50 [60]. Tea consumption was indicated as either never, 
sometimes, 1-2 cups/day or 3+ cups/day. When assessing males, the intake of tea was 
linked to a reduction in rate of fracture, regardless of dose [60]. Likewise, women were 
also found to have a lower rate of fracture when they consumed tea [61]. 
Both cross-sectional studies and prospective studies suggest a trend exists in 
which habitual consumption of tea can have effects on bone health by increasing BMD in 
women. Those who were considered regular habitual tea drinkers were shown to have 
higher BMD that could translate to a lower risk of fragility fracture. Females were the 
general focus of these studies, and where males were incorporated, tea consumption was 
generally not positively associated with BMD at any skeletal site. The general lack of 
effect within male populations may be attributed to the evidence that flavonoids are 
acting as estrogenic mimics and therefore have little benefit.  
Unlike females after menopause, males produce testosterone throughout their 
lifetime, and therefore still have the ability to produce estrogen late in life (via aromatase) 
[62]. Therefore, this ability to produce estrogen means that flavonoids would have to 
compete with estrogen for binding to its receptor as estrogen will bind to estrogen 
receptors with a higher affinity than flavonoids.  Moreover, flavonoids are present at low 
concentrations within plasma. Furthermore, the majority of cross-sectional and 
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prospective studies include consumption of many different tea types (black, oolong, 
green, rooibos) and due to the differing compositions (i.e. flavonoids, caffeine, etc.), 
certain types of tea may produce different biological effects.  However, the study in 
Taiwan that reported a positive relationship amongst consumption of tea and BMD also 
analyzed BMD between individuals who consumed green tea or oolong tea versus those 
who consumed black tea. Analysis between these groups found that there was no 
difference in BMD across tea types [53]. The consumption of tea and how it relates to 
rate of fracture studies is controversial; as studies across six European countries have 
identified both men and women who consume tea on a regular basis had a lower rate of 
fracture [60,61]. Women who had participated from Sweden or the Women‟s Health 
Initiative did not show a negative correlation between tea consumption and fracture [56-
57]. Therefore, with the current information, no conclusion can be made on how tea 
impacts rate of fracture. 
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Table 1.1 Summary of Cross-Sectional and Prospective Studies Investigating Tea Consumption and BMD 
Study Country of Study, 
Sample Size, Sex, 
Age 
Tea 
Consumed* 
Type of Study Effects 
Hoover and 
coworkers[45] 
Canadian 
n = 62  
F 
+57yrs 
Tea 
consumers  
Cross-sectional Tea consumption was positively correlated to 
BMD at the lumbar spine (p < 0.01) and 
femoral neck (p < 0.01).   
Hakim and 
coworkers[56] 
American 
n = 91,465 
F 
+50yrs 
<1 cup/day 
 1 cup/day 
2-3 cups/day  
>4 cups/day 
Cross-sectional Tea consumption was positively correlated to 
total body BMD (p < 0.05). There was no 
association between tea consumption and total 
hip BMD (p = 0.22) or lumbar spine and 
BMD (p = 0.06). Individuals who drank at 
least 4 cups/day had greater total body BMD 
than individuals who drank 1 cup/day (p 
<0.05). Individuals had higher BMD at the 
spine when they consumed between 2-
3cups/day than 1 cup/day (p < 0.05). 
Devine and 
coworkers[52] 
Australian 
n = 1,027 
F 
+70yrs 
Tea 
consumers  
Cross-sectional Tea consumers had a significantly higher 
BMD in comparison to non-consumers for 
total hip (p < 0.05) and trochanter (p < 0.01) 
BMD 
Hegarty and 
coworkers[46] 
English 
n = 1,256 
F 
+65yrs 
Tea 
consumers 
1-3 cups of 
tea/day, 4+ 
cups of 
tea/day 
 
Cross-sectional Tea consumers had 5% greater BMD at 
lumbar spine (p < 0.05), greater trochanter (p 
= 0.004) and Ward‟s triangle (p < 0.05) than 
non-consumers. 
No difference in BMD when amount of tea 
consumed was compared. Addition of milk 
did not result in any differences  
Muraki and 
coworkers[47] 
Japanese 
n = 632 
Green tea 
consumers 
Cross-sectional Consumers of Green Tea had higher BMD 
and better T-scores (-1.592.70 versus -
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F 
+60yrs 
2.172.08) at the lumbar spine than those who 
did not consume tea (p<0.05) 
Larijani and 
coworkers[48] 
Iranian 
n = 830 
M, F 
+20yrs 
Habitual tea 
consumers  
(≥5 cups of 
tea/day) 
Cross-sectional Women whom habitually consumed tea 
showed a lower frequency of osteoporosis 
(5.6% versus 12.1%) and osteopenia (24.5% 
versus 36.5%) compared to non-consumers. 
No significant difference in prevalence of 
osteoporosis when assessing the male 
population.  
Women who habitually consumed tea in 
general had higher BMD at the spine, but was 
not shown to be significant (p < 0.07), but did 
show greater BMD at the hip (p = 0.01). 
Among males, no differences in BMD of 
consumers and non-consumers. 
Kyriazopoulos 
and 
coworkers[50] 
Greek 
n = 300 
M 
18-30yrs 
Tea 
consumption 
Cross-sectional No association amongst tea intake and BMD 
or tea intake and bone mineral content of the 
distal and ultra-distal radius (p <0.05).  
Saitoglu and 
coworkers[51] 
Turkish 
n = 70 
M 
45-65yrs 
Tea 
consumers 
Cross-sectional No association amongst tea consumption and 
BMD (p > 0.05). 
Vestergaard 
and 
coworkers[49] 
Danish 
n = 2,016 
F 
45-58yrs 
Tea 
consumption 
Cross-sectional Tea consumption was positively associated 
with T scores above -0.75 for BMD at the 
femoral neck.   
Ungan and 
coworkers[54] 
Turkish 
n = 727 
F 
+48yrs 
> 2 cups of 
tea/day 
Cross-sectional No statistical difference between BMD of tea 
consumers and non-consumers when 
measured across three phalanges  
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Ungan and 
coworkers[54] 
Turkish 
n = 727 
F 
+48yrs 
> 2 cups of 
tea/day 
Prospective 
(1 year in 
duration) 
No statistical difference between tea 
consumers and non-consumers in osteoporosis 
prevalence  
Hardcastle 
and 
coworkers[55] 
Scottish  
n = 3,226 
F 
45-54yrs 
Flavonoid 
consumption 
Prospective  
(5-9 years in 
duration) 
57% of flavonoid intake was attributed to 
consumption of tea  
Total flavonoid levels were correlated with 
femoral neck (p < 0.01) and lumbar spine (p < 
0.05) BMD. 
Catechins and Procyanidin levels were 
correlated with % annual change in BMD at 
the femoral neck and BMD at the lumbar 
spine (p < 0.05). 
Total flavonoids were negatively correlated to 
free deoxypyridinolines (p < 0.05). 
A higher flavonoid intake relates to lower rate 
of bone resorption (p = 0.001).  
Wu and 
coworkers[53] 
Taiwan 
n = 1,037 
M, F 
+30yrs 
Habitual 
versus non-
habitual tea 
consumption 
 
Categories: 
1-5 years,  
6-10years 
>10years 
Prospective 
(2-4 years in 
duration) 
Tea consumers (for 6 or more years) had 
greater BMD at the lumbar spine BMD (p < 
0.01) and hip (at the neck and Ward triangle, 
p < .05) and total body BMD (p < 0.001) than 
non-consumers.  
There was no statistical significance in BMD 
at any site when tea was consumed less than 
5yrs (p > 0.05). 
No change in BMD when individuals 
consumed green or oolong tea versus black 
tea.  
Devine and 
coworkers[52] 
Australian 
n = 164 
F 
+70yrs 
Tea 
consumers 
Prospective 
(5 years in 
duration) 
Tea consumers lost 1.4% of total hip BMD 
versus non-consumers who lost 4.7% in the 
fully adjusted model (p < 0.01).  
Tea consumers lost 2.0 % of trochanter BMD 
versus non-consumers who lost 6.3% (p < 
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0.01). 
Tea consumers lost 1.0% of intertrochanter 
BMD versus non-consumers who lost 4.5% (p 
< 0.01). 
* “tea consumers” refers to whether individuals were tea consumers or not with no quantification of how much tea they 
habitually consumed. Tea consumed includes consumption of all tea (green, black, oolong, herbal tea) and type of tea 
consumed was not measured unless specified.  
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Table 1.2. Summary of Prospective Studies Investigating Tea Consumption and Fracture 
Study Nationality, 
Sex, Age 
Tea 
Consumed 
Duration 
of Study 
Outcomes 
Kanis and 
coworkers[60] 
European 
n = 1,762 
M 
+50yrs 
Tea consumers 
or non- 
consumers 
1 year Tea consumers had a lower rate of hip fracture  
(p < 0.001) than non-consumers. 
Johnell and 
coworkers[61] 
European 
n = 5,618 
F 
+50 yrs 
Tea consumers 
or non- 
consumers 
1 year Tea consumers had a lower rate of hip fracture  
(p < 0.001) than non-consumers. 
Hallstrom and 
coworkers[57] 
Swedish 
n = 31,527 
F 
+40yrs  
Black tea 
<1 cup/day,  
1 cup/day,  
2-3 cups/day, 
≥ 4 cups/day 
 10.3 years No significant difference in incidence of fragility fracture 
between consumers and non-consumers.  
Chen and 
coworkers[56] 
American 
n = 91,465 
F 
+50yrs 
<1 cup/day,  
1 cup/day, 
 2-3 cups/day, 
>4 cups/day 
 4.1 years No significant difference in incidence of fragility fracture 
between consumers and non-consumers. Fractures were 
listed as hip fractures, forearm or wrist fractures and other 
fractures. 
 
Herbal and decaffeinated tea was not included for tea 
consumption. 
Jha and 
coworkers[58] 
Indian 
n = 100 
M F 
65 yrs# 
≤ 1 cup/day, 
> 1 cup/day 
Cross-
sectional 
Tea consumers had a higher fracture risk (p < 0.001) 
Du and 
coworkers[59] 
Chinese 
n = 703 
M F 
90+yrs 
Tea consumers 
or non- 
consumers 
Cross-
sectional 
No association between tea consumers and non-consumers 
with rate of fracture 
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* “tea consumers” refers to whether individuals were tea consumers or not with no quantification of how much tea they 
habitually consumed. Tea consumed includes consumption of all tea (green, black, oolong, herbal tea) and type of tea 
consumed was not measured unless specified. 
M = male, F = female 
# the age listed is an average
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1.4.2 Composition of Tea 
 
Tea from the leaves of Camellia sinensis or herbal sources (Aspalathus linearis) 
contain an abundance of diverse flavonoids which help provide antioxidant, anti-cancer, 
anti-bacterial activity. Along with trace elements taken up from the soil, tea may also 
contain larger concentrations of caffeine, fluoride, and flavonoids, all of which can 
impact health [63]. A combination of caffeine, fluoride and flavonoid content could lead 
to different biological activities in a system, and these combinations can vary depending 
on season, location, the age of the plant and how it is processed [64]. 
 
1.4.2.1 Caffeine  
 
Caffeine, a diuretic, is found in most tea, including green, oolong, and black tea, 
but not within rooibos tea.  Black tea is recognized for containing the largest 
concentration of caffeine per cup (8oz) [65], but even this is considerably less than coffee 
[66]. High consumption (≥4 cups/day of coffee [67]) of caffeinated beverages can be a 
concern for bone health with its ability to limit calcium absorption into the blood steam 
through urinary loss [68], and this has been associated with accelerated bone loss in 
elderly women [69]. However, calcium absorption measured in pre-menopausal women 
whom were given 400mg/day of caffeine over 19 days, demonstrated no difference in 
calcium levels when compared to controls [70]. On the other hand, caffeine intake has 
been shown to have significant negative effects on fasting serum phosphorous levels and 
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bone turnover markers [70]. Furthermore, a study in Sweden which followed women ages 
40-76 over 10 years found that excessive caffeine intake equating to over 300 mg of 
caffeine a day was related to a moderate increase in osteoporotic fracture, but attributed 
this to be partially due to lack of calcium intake [57]. A study that assessed BMD at 5 
sites on the bodies of postmenopausal women across three different countries did not 
detect a relationship between caffeine intake and BMD [71]. More recently, a study that 
analyzed data from 38,984 women from the Swedish Mammography Cohort 
demonstrated that increased coffee consumption was not related to an increased rate of 
fracture. Although, a high intake of caffeine (≥4 cups/day) was linked to slightly lower 
spine (4%), proximal femur (2%) and total body (2%) BMD compared to women who 
consumed < 1 coffee/day [72]. Additionally, women who consumed below 745mg of 
calcium/day that also ingested high levels of caffeine (≥450 mg/day) had significantly 
lower spine and total BMD. When calcium levels were above 745mg/day, this effect of 
caffeine on spine and total BMD was lost [73]. 
1.4.2.2 Fluoride  
 
Fluoride, is another common element found in tea, has been suggested to be able 
to manipulate bone metabolism. The levels of fluoride in tea depend on the drinking 
water used for boiling the tea leaves in. When postmenopausal women with osteoporosis 
were given 75 mg/day of fluoride and supplemented with 1500 mg of calcium per day, 
they experienced increased BMD at sites with high ratios of trabecular bone to cortical, 
but were reduced in sites of high cortical bone. Furthermore, there was an increase in 
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non-vertebrate fractures in the individuals consuming fluoride, suggesting that fluoride is 
not beneficial for bone health [74].  
This heavy consumption of fluoride is now recognized as fluorosis, in which high, 
repeated exposure to fluoride can result in fluoride accumulating in the bone matrix. This 
new fluoride embedded in the mineral has not only suggested to be resistant to bone 
turnover but also possesses the ability to change the microarchitecture of the bone 
through the production of ionic bonds with nearby calcium atoms [75]. Although rare, 
there have been several reports published on individual cases where increased 
consumption of tea, high in fluoride, has resulted in consumption of fluoride levels that 
were orders of magnitude more than the average individual [76]. This new 
microarchitecture, referred to as fluorapatite, now represents a new crystalline structure 
from the previous hydroxyapatite. This fluoride-substituted crystal has been identified as 
having lost elasticity and tensile strength [77]. 
 
1.4.2.3 Flavonoids 
 
Many of the potential benefits of flavonoids in bone metabolism may be due to 
effects that mimic estrogen, i.e. anti-oxidant activity and/or increasing apoptosis and 
decreasing activity in osteoclasts, thereby enhancing the activity and differentiation of 
osteoblasts. Therefore, a brief overview of how estrogen acts on bone tissue is provided. 
Studies showing a positive relationship between consumption of tea and BMD [45-48] 
may be due to its flavonoids having a role in regulating inflammation and cellular stress 
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via antioxidant activity. In addition, flavonoids may enhance the production and regulate 
bone markers by interacting with osteoblasts, while inhibiting activity and/or increasing 
apoptosis in osteoclasts [78,79,80]. With this wide range of biological influence, but lack 
of information regarding bone health (especially within human cell lines), these 
flavonoids are seemingly a promising step to finding a natural product to increase bone 
mineral density while offering benefits to other aspects of health.     
As demonstrated through menopause, estrogen is a key player in the lifecycle of 
our bones. Produced primarily by the ovaries, estrogen binds to estrogen receptors (ERα, 
ERβ) found on various cell types in order to promote a biological change.  A loss of 
estrogen (i.e. menopause, oophorectomy) has been linked to a large loss in BMD and 
strength, equating to a higher likelihood of a fragility fracture [81,82].  
Mutations within genes that express estrogen receptors and enzymes such as 
aromatase have led to low BMD and skeletal problems [83,84]. Nevertheless, suppression 
of androgen production, or mutations within androgen receptors may also leave males 
with similar characteristics of extreme bone mineral loss and reduced bone strength 
[85,86]. When older men were given testosterone and/or estrogen inhibitors and followed 
by hormone replacement for either androgen or estrogen, estrogen replacement prevented 
70% of the effects of bone turnover, while testosterone accounted for the other 30%. 
Bone turnover was measured by changes in bone creation and destruction markers such 
as ALP and deoxypyridinoline, respectively. In addition, estrogen was the only hormone 
significantly involved in both the creation and destruction of bone [87].  
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1.5 Rooibos tea 
 
Rooibos (Aspalathus linearis) tea contains a high level of flavonoids and is 
naturally located in the mountainous areas of Western Cape, South Africa. The plant 
contains very thin, needle-like leaves in which they can be used for fermented (green 
rooibos) or unfermented tea (red rooibos) [88,89]. Rooibos has attracted recent interest 
due to it containing a large concentration of flavonoids and lack of caffeine content, 
therefore potentially providing the benefits of green and black tea, without the detriments 
of a diuretic.  
Rooibos tea is known to contain many flavonoids that possess the ability to 
scavenge free radicals [90]. Free radicals occur due to extra single electrons found on 
oxygen species (OH and O2) formed during oxygen metabolism. If these free radical 
species are left and concentrations become too high, they will extract electrons from 
nearby macromolecules such as DNA and lipids, which result in cellular death [91]. 
Compounds that can extract and neutralize these free radicals are highly sought after by 
scientists, nutritionists and doctors, and take the form of multi-cyclic ring systems in 
which the free radical charge can be shared across the ring systems [90]. Flavonoids 
within rooibos tea contain multiple cyclic ring systems, making them the perfect free 
radical scavenging, macromolecular saving systems [89]. When antioxidant activity of 
green, oolong, black, unfermented rooibos, semi-fermented rooibos and fermented 
rooibos, were compared, green tea contained the best free-radical scavengers with an 
inhibition of 90.8% of the free radicals, while unfermented rooibos came in a close 
second with an inhibition success of 86.6% [92]. In contrast, a study in 2003 suggested 
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that black tea contained not only a higher concentration of flavonoids, but also out-
competed rooibos tea, (fermented and unfermented) in antioxidant activity [93]. Rooibos‟ 
antioxidant power was further shown to be extensive when rooibos tea was able to reduce 
lipid peroxidation within rats when livers were introduced to fumonisin, a free radical 
agent that promotes liver cancer [94]. These results of rooibos‟ antioxidant potential were 
further fortified in a human study, where participants ingested rooibos tea daily (6 
cups/day) for 6 weeks. Total plasma flavonoid concentrations of the subjects increased 
while lipid peroxidation decreased by. Additionally, reduced glutathione-to-oxidized 
glutathione ratio dramatically increased with consumption of rooibos tea and was 
maintained after completion of the study [95]. Therefore tea with high levels of 
flavonoids may be beneficial to limit reactive oxygen species and inflammation. 
Flavonoid content varies in tea depending on the tea‟s grade. Rooibos production 
was examined from 2009-2011 with differing quality grades, A through D, with A being 
the highest quality. A positive trend was identified in which higher grades of tea were 
associated with higher flavonoid concentration. There were significantly higher 
concentrations of individual flavonoids in higher grades of rooibos tea such as: 
aspalathin, isoquercetin, rutin, hyperoside, quercetin-3-O-robinobioside, suggesting 
higher grades of rooibos tea would be more efficient food sources of flavonoids [96].  
Whether the tea is unfermented or fermented can change the chemical composition of the 
tea extract in addition to its bioavailability and activity. A review of rooibos tea compared 
differing concentration of flavonoids from fermented and non-fermented rooibos tea in 
100g of dried tea leaves from three different fermented and three different unfermented 
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plant sources. The flavonoids focused on from this study, found in rooibos tea, in both 
fermented and unfermented conditions are listed in Table 1.3 [44]. 
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Table 1.3. Concentration of selected flavonoids in fermented and unfermented rooibos tea and other food sources 
Flavonoid Structure Fermented  
(g/100g) [44] 
Unfermented  
(g/100g) [44] 
Average 
Weight in 
Rooibos tea 
(mg/500ml) 
[97] 
Plasma 
Range after 
3hr ingestion 
(nmol)[97] 
Other food sources [98, 99] 
(mg/100g) 
Orientin 
O
OH
OH
OH
OH
OOH
OH
OH
OH
O
 
0.263  0.087 0.202  0.026 17 0.0-0.7243 Buckwheat malt (80.9mg), 
Olives (0.22mg) 
Rutin 
OOH
OH O
OH
OH
O
O
O
OH
OH
OH
O
OH
OH
OH
CH3
 
0.245  0.141 0.173  0.016 7.9 0.0-0.4686 Capers (332.29mg), 
Buckwheat malt (102.1mg) 
Buckwheat whole grain 
flour (37.27mg), black 
raspberries (19.00mg), 
Olives (45.36mg), 
Asparagus (23.19mg) 
Hyperoside 
OOH
OH O
OH
OH
O
O
OH
OH
OH
OH
 
0.021  0.012 0.016  0.015 0.8 ND American cranberry 
(10.81mg), Lingonberry 
(13.22mg), Black 
Chokeberry (46.46mg), 
Black tea (4.17mg) 
Luteolin 
OOH
OH O
OH
OH
 
0.007  0.006 0.010  0.005  Not tested  Mexican oregano 
(56.33mg), Thyme 
(39.50mg), Sage (33.40mg), 
artichoke (42.10mg) 
SD =  standard deviation, ND = not detected 
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Although the flavonoid content can differ by large concentrations, a study done by 
Serafini and coworkers [100] suggests that both the fermented and unfermented rooibos 
tea contain considerably large amounts of antioxidant activity. When consumed, the 
fermented tea resulted in a 6.6% higher antioxidant capacity within plasma. Unfermented 
tea had a 2.9% higher antioxidant capacity than the control. These findings suggest 
rooibos may be a source of nutritional antioxidants. In contrast to this, Marnewick [101] 
did not find an increase in plasma antioxidant status after volunteers drank rooibos tea 
daily for 6 weeks. But, a significant increase was noted in total flavonoid content within 
plasma. A large drop in lipid peroxidation, serum low-density-lipids was also noted, 
while a significant increase was found in reduced glutathione, high density lipids and 
triacylglycerols, all of which are beneficial to cardiovascular health. The ability for tea to 
change important biological characteristics such as antioxidant status, lipid peroxidation, 
and levels of low-density-lipids allow them to be characterized as bioactives. Bioactives 
are molecules that can exhibit a change in a biological system through their interaction 
with receptors and proteins at the molecular level.   
Antioxidants play several roles within bone health, the first being that osteoclasts 
secrete free radicals to aid in the digestion of mineral by stimulation of cytokines which 
increases osteoclast differentiation and activity. Therefore the application of antioxidants 
such as vitamin E has been shown to help remove these free radicals thereby limiting 
bone resorption and optimizing growth [102]. It is currently understood that free radicals 
can increase production of NF-κβ that activates bone resorption. Basu and coworkers 
[103] looked at the relationship between a biomarker for oxidative stress (8-iso-PGF2a) 
and BMD in a small group of men and women. They discovered a negative, linear 
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association with 8-iso-PGF2a and total BMD as well as 8-iso-PGF2a and BMD at the 
lumbar spine. Moreover, free radicals have been shown to inhibit osteoblast 
differentiation. These effects could then be counteracted by treatment with antioxidants 
[104]. Evidence has shown that during estrogen deficiency there is a loss of anti-oxidant 
defense systems producing a more suitable environment for osteoclast differentiation 
[105]. The administration of antioxidants to ovariectomized mice has prevented bone 
loss. Glutathione peroxidase, the dominant enzyme found within bone systems to deal 
with free radicals is up-regulated in the presence of estrogen, and therefore during 
estrogen deficiency, this defense is largely reduced [105,106]. This evidence suggests 
that flavonoids from rooibos tea may play a role in limiting osteoclast proliferation while 
aiding in the production of osteoblasts, allowing for the body to maintain healthy bones.  
Anti-cancer, anti-fungal, anti-viral activities as well as potential effects on bone 
cell activity are all important characteristics of rooibos flavonoids [94,107,108,109,110]. 
The ability for these flavonoids to produce biological changes within both cells and 
organisms suggests that they can interact with cellular receptors and enzymes to up/down 
regulate different genes and therefore alter multiple mechanisms. The in vivo models in 
which flavonoids were detected in plasma suggests that these flavonoids can enter plasma 
after consumption and exert biological effects that are beneficial to the animal. This data 
suggests that flavonoids may possess the ability to not only interact with important 
receptors involved in bone metabolism, but also modulate them to improve bone health.   
As these compounds show activity in biological systems, it is imperative to 
understand the metabolism of these compounds, the tissues they partition into, and at 
what concentrations. The bioavailability and antioxidant status of flavonoids found within 
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rooibos tea after human ingestion were therefore examined in 12 healthy males. 
Participants were provided a placebo, rooibos tea or the isolated flavonoid fraction. 
Flavonoid content was initially analyzed using 10g of dried leaves in 500ml of boiling 
water in which the compounds were detected using high performance liquid 
chromatography (summary in Table 1.3). Only Aspalathin, isoorientin, orientin, rutin, 
vitexin and isovitexin could be detected in plasma [97].  
The flavonoids of interest within this study are: orientin, rutin, hyperoside and luteolin. 
These flavonoids were chosen for the following reasons:  
i. Some cross-sectional and prospective studies suggest that tea consumption 
may improve BMD, and within some studies, tea consumption is negatively 
correlated to fracture. Therefore, there is a strong possibility that the 
flavonoids in tea are mediating this biological effect. Flavonoids found in 
larger concentrations within tea, that are readily quantifiable in tea extracts are 
of more interest due to their likelihood of bypassing the first pass effect and 
entering plasma to produce a biological outcome.  
ii. These four flavonoids feature antioxidant, antifungal, anticancer and 
antibacterial characteristics. This vast and increasing range of activity has 
increased the interest of these compounds, leading to a growth in production  
within chemical companies, providing research laboratories with more access 
to them. 
iii. With this wide range of biological influence, but lack of information regarding 
bone health, especially within human cell lines, these flavonoids are 
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seemingly a promising step to finding a natural product to increase bone 
mineral density while offering benefits to other aspects of health. 
iv. Due to the ability of orientin, and rutin, to enter plasma through consumption 
of rooibos tea, it is recognized that these compounds are the most 
physiologically relevant flavonoids when developing dietary strategies for 
disease prevention or management of a disease.  
v. Other studies have reported the ability of hyperoside to enter plasma after 
consumption of other food and beverage [111,112,113]. In addition, luteolin is 
documented for its lack of ability to enter plasma through tea consumption, 
but has been identified in plasma of human and mice after oral consumption of 
luteolin (in its free form – not glycosylated) [114]. Therefore, it is not only 
important for scientists to understand the particular flavonoid of interest in a 
specific consumable (i.e. rooibos tea), but in addition, the flavonoid and its 
concentration found within other food or beverages.  
vi. As many of these compounds resemble each other‟s structures with slight 
differences in position of hydroxyl or sugar components, changes in activity 
from one compound to the next will allow for a better understanding of how 
chemical structure may influence up or down regulation of important genes in 
bone turnover. Changes in positions of functional groups that result in 
different activity in bone cells will allow for a deeper knowledge of important 
functional positions. These positions will bring about information on possible 
steric hindrance that disallows interactions between substrates and receptors, 
while also identifying key bond relationships that may enhance or hinder 
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activity. With an idea of which enzyme or receptor a flavonoid may interact 
with, these interfaces can be modeled in silico to further develop our 
understanding of structure-function relationships which may help in decoding 
possible mechanisms.   
 
1.5.1 Rooibos Flavonoids and Metabolism 
 
When working with flavonoids, it is important to recognize the metabolic 
pathway in which the flavonoid is partitioned, broken down and removed from the body 
as not all flavonoids reach plasma in their ingested form. In addition, having a good 
understanding of the working metabolites of these flavonoids can present new ideas on 
the specific fragments of the structure that are important for improving bioavailability 
(Figures 1.3-1.6). With recent studies suggesting that tea flavonoids can influence bone 
turnover [115,116,117] and with sales of rooibos tea increasing, it is of great interest to 
understand potential influences that these specific flavonoids will have on bone cells. 
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 1.5.1.1 Orientin 
Figure 1.3. Metabolism of Orientin.  The above diagram outlines the metabolites of 
orientin and the tissues that are responsible for metabolism. Information is adapted from 
references [97].  
Orientin, another bioactive found within human plasma after consumption of 
Rooibos tea [97], will undergo hydrolysis to produce luteolin or can be hydrogenated into 
3‟,4‟,5,7-tetrahydroxy-flavanone-6-glucoside  which can be subsequently deglycosylated 
and undergo ring cleavage into smaller phenolic compounds such as hydrocaffeic acid 
and phloretic acid (Figure 1.3).  
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1.5.1.2 Rutin 
 
Figure 1.4. Metabolism of Rutin.  The above diagram outlines the metabolites of rutin 
and the tissues that are responsible for metabolism [118].   
Ingestion of rutin leads to production of quercetin and 3,4-dihydroxyphenylacetic 
acid in the large intestine which is further metabolized by the liver into 3-
hydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid. Quercetin and 
rutin are both found in plasma [118].  
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1.5.1.3 Hyperoside 
 
 
Figure 1.5. Metabolism of Hyperoside. The above diagram outlines the metabolites of 
hyperoside and the tissues that are responsible for metabolism [118, 119].  
Hyperoside, when ingested has been reported both in and absent from plasma, 
produces major metabolites after going through the first pass effect in which the liver 
produces a methylated form. This methylated form is then sulfated and glucuronidated 
[119]. Hyperoside is also known to be a major metabolite of aspalathin [118].  
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1.5.1.4 Luteolin 
 
 
Figure 1.6 Metabolism of Luteolin. The above diagram outlines the metabolites of 
luteolin and the tissues that are responsible for metabolism [120,121].   
Consumption of luteolin in its pure form will lead to methylation products 
(chrysoeriol 3‟-O-methylation, and disometin: 4‟-O-methylation) within the liver 
produced through a transfer mechanism which involves a methyl group being transferred  
from S-adenosyl-L-methionine to a hydroxyl in the substrate via catechol-O-
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methyltransferase. These can also be demethylated via cytochrome P450‟s (CYP1A2 and 
CYP34/5). Furthermore, luteolin is sulfated by uridine-5-diphosphate sulfotransferases 
and glucuronidated by glucoronosyl transferases [120,121].  
 
1.6 Drug Discovery  
 
While nutritional science generally first considers what flavonoids are present in 
plasma after ingestion of food, there is a rationale for studying flavonoids that are not 
present in high amounts or detectable amounts in plasma. Flavonoids with poor 
bioavailability can undergo alterations to improve pharmacokinetics such as modification 
to its structure or the encapsulation of the compound. For example, interestingly, luteolin 
has become of recent interest due to its inhibitory effects on β-hydroxyacyl-acyl carrier 
protein dehydratase of Plasmodium falciparum. Plasmodium falciparum is a bacterium 
responsible for malaria, and the dehydratase enzyme is responsible for allowing fatty acid 
biosynthesis within the infected host [122]. This compound was initially discovered after 
epigallocatechin gallate was shown to provide antibacterial and antifungal activity within 
many organisms that involve the inhibition of fatty acid synthase [123]. From there, a 
chemical library was developed in which flavonoid compounds were stored with 
information regarding their solubility, size, and biological information.  Through 
screening methods, in silico experimentation and enzyme purification procedures, 
luteolin was discovered to be an efficient inhibitor for the dehydratase and thus a 
potential route for medicine [122]. If fatty acid biosynthesis cannot occur in the host, 
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successful transmission of the parasite is lost and is thus an important area of research for 
vaccine and drug development.  
Looking at structure-function relationships using in vitro methods can positively 
lead to drug targets in which chemical synthesis can improve upon structure details to 
allow for increased bioavailability, longer/shorter half-lives and improved molecular 
interactions [124]. In Cragg‟s recent review (2013) on drug discovery, approximately 
50% of new drugs are either natural products, natural products with synthetically 
modifications or synthetically produced drugs based on natural products.  This percentage 
increases to 64% when considering synthetic compounds used to inhibit natural product 
substrates [125].  
Natural health products have been recognized for millions of years for treatment 
of sores, rashes, fever, and are still largely within the pharmaceutical industry. Some of 
the most profitable and useful medications came from nature, such as morphine and 
ephedrine. Many compounds are also naturally derived but synthetically modified to 
improve pharmacokinetics. One example is quinine, which is isolated from the bark of 
the tree species Cinchona, which served as the basis for anti-malarial drugs [125]. 
Another compound known as digitalis that is derived from the foxglove plant has been 
chemically modified for medicinal treatment of heart failure [126]. Thus, it is important 
to understand and assess both compounds that enter plasma through tea consumption and 
those tea flavonoids that have the ability to enter plasma, but through other means, in 
their ability to manipulate bone mineralization.  
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1.7 Bone Culture Systems 
  
Bone cell cultures are important for studying biochemical mechanisms in which a 
biological change is noted. They offer a faster, less costly and more controlled, detailed 
method for looking at protein and receptor interactions than working with in vivo models. 
Cells also allow for multiple replications in addition to studying multiple signaling 
pathways. Cell cultures are key for targeting pathways of interest and the development of 
drugs and vaccines for treatment of diseases such as osteoporosis.  
When focusing on prevention of osteoporosis it is important to understand the 
affect the dietary component or drug has on both osteoblast actions as osteoblasts are 
important for the production of bone matrix and mineral. In vitro models utilizing human 
osteoblasts can help assess changes in the cell cycle and protein production that may 
favorably enhance bone production by osteoblasts. When studying new flavonoids, 
osteosarcoma cell lines (i.e. Saos2 cell line) make perfect candidates for analyzing 
changes in cell mechanisms due to their ability to differentiate into mature osteoblasts, 
continuously replicate while also containing similar properties to primary human 
osteoblasts. Common human osteosarcoma cell lines are: MG-63, U2 and Saos2 [127].   
 
1.7.1 Saos2 Cells 
 
First recognized by Fogh in the mid-70s, Saos2 cells, a human cell line from 
osteosarcoma, have been well characterized and established for studying how dietary 
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components such as flavonoids affect osteoblast activity [128]. For example, Saos2 cells 
are also well known for their high ALP activity ranging from 4-6µmol/min/mg protein 
which makes them great candidates for studying the effects of flavonoids on mineral 
deposition. Other osteosarcoma cell lines from human or mouse contains low ALP 
activity consistent around 2.5nmol/min/mg protein ultimately translating to less mineral 
being produced in a period of time [129]. Another advantage of using the Saos2 cell line 
is that it endlessly proliferates which allows for less variation when researchers use a 
specific population to target cell mechanisms. As a primary cell line cannot grow 
indefinitely, assessing different mechanisms within osteoblasts can be time consuming, 
and it is best to limit variation that can exist in passage number and population. Saos2 
cells also increase its rate of proliferation as the passage number increases, this allows for 
larger population studies while keeping costs low [130]. Steroid receptors are important 
features for osteoblastic cell lines, especially because many flavonoids are believed to 
manipulate bone formation through mimicking the substrates for these receptors. Keenan 
et al., reported androgen (1605 sites/cell) and progesterone receptors (119 sites/cell) in 
the Saos-2 cell line, but failed to detect estrogen receptors. Concentrations of androgen 
and binding sites are approximately 21 times higher in Saos2 cell lines than rodent 
osteoblasts, and are a better representation of human primary osteoblasts [131]. In 2007, 
Sekeris and co-workers published their findings of both the α-ER and β-ER are found in 
the nucleus and cytoplasm, respectively [132]. Receptors for 1,25(OH)2D3, the active 
form of vitamin D, are also present within this cell line which are similar to those found 
in primary human cell lines, making them more representable as natural osteoblastic 
cells. This receptor has importance in its ability to enhance the production of a protein 
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known as osteocalcin [129]. Furthermore, these cells have become of great interest for 
their ability to differentiate into osteoblasts, allowing mechanistic studies on 
transformation that mimic those of primary cell lines. This suggests that Saos2 cell lines 
are good representatives of primary cell lines as they present similar receptor types, 
number of sites and differentiate in the same manner. These characteristics are helpful 
when looking at mechanistic studies involving changes in osteoblast activity as they are 
more likely to represent what is occurring in a primary cell line.  
As with most model systems, there are some disadvantages to working with this 
cell line. These disadvantages include the lack of genes found in primary bone cells that 
could potentially change how compounds influence bone growth. The Saos2 cell line 
does not contain RUNX-1 or RUNX-3, only RUNX-2. RUNX-1 is responsible for 
differentiation of hematopoietic cells [133]. RUNX-2 coordinates the growth factors that 
allow for bone development and osteoblast maturation [134]. RUNX-3 controls the up-
regulation and down-regulation of transcription factors and its removal is often associated 
with cancerous cells (i.e. Saos2 cells) as it is linked with the tumor suppressor factor 
[135,136]. Although this demonstrates a difference between primary cell lines and the 
Saos2 cell line, having only RUNX-2 does have its benefits. This availability of RUNX-2 
and lack of RUNX-1 and -3 allow for mechanistic studies on this gene and its 
involvement with mineral deposition. In a study done by Jean-Christophe and Odile, 
Saos-2 cells were transfected with small interfering RNA (siRNA) to knock out RUNX-2 
in order to evaluate the gene‟s involvement in proliferation and differentiation. This 
resulted in an extreme reduction in the cyclin inhibitor p21 which mediates anti-
proliferation mechanisms within osteoblasts. There was also a decrease in Bax protein 
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expression, a protein that regulates apoptosis. Tumor necrosis factor (TNF), a cytokine 
that can naturally induce cellular death within osteoblasts was inhibited when RUNX-2 
was introduced to siRNA, suggesting that RUNX-2 has an important role in maintaining 
the ability of the osteoblast to differentiate and proliferate [137]. Primary human 
osteoblasts and the osteosarcoma cell line MG-63 have been recognized for their ability 
to proliferate under mechanical stimuli, much like the human body experiences when 
exercising. Jones and coworkers tested this ability in other osteosarcoma cell lines 
including Saos2 cells and found that proliferation was not increased under the same 
stimuli. This was believed to be due to the lack of phospholipase C β2, a protein believed 
to be expressed and up-regulated in cells sensitive to mechanical stimuli [138]. This is 
another representation of the lack of genes, or protein production that an osteosarcoma 
line such as Saos2 has in comparison to a primary cell line. Hausser reported the 
phenotypic instability of Saos-2 cells after recognizing the negative association between 
passage number and ALP activity. This pattern was also seen with Decorin, a gene 
suggested to control proliferation and mineralization. Decorin expression was 
significantly reduced after 20 passages, in which proliferation and mineral deposition 
dramatically increased [130]. This data is important for acknowledging that the use of the 
osteosarcoma cell line Saos2 requires experiments to contain controls of the same cell 
population and passage number to reduce variation.  
 With Saos2 cells closely resembling primary bone cells, these cells offer a method 
for clean replication of cell signaling analysis in a human cell line that is more likely to 
mimic those of primary cells than lines originating from other species. Saos2 provides a 
reasonable starting point for investigation into the effects of flavonoids on mineral 
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deposition in humans. Acknowledging the benefits of producing similar genes, receptors 
and protein interactions between Saos2 and primary human osteoblasts, gives reason to 
believe that results achieved using this osteosarcoma cell line will have a reasonable 
chance to be replicated in a human primary cell line. In saying so, results that achieve 
potential for enhanced mineral deposition should be investigated further within a human 
primary cell line to ensure accuracy and full creditability, and ultimately, tested in vivo.  
Chapter 2.0 - Objectives and Hypotheses 
The overall objective is to determine if the addition of purified rutin, hyperoside, 
orientin and luteolin to Saos2 cells, will result in greater mineral content. Secondary 
objectives are to determine potential mechanisms as to why the addition of rutin, 
hyperoside, orientin and luteolin results in greater mineral content, these are: osteoblast 
activity as defined by ALP, cell mitochondrial activity, cell toxicity, and changes in 
osteoblast regulatory protein production.  
2.1 Specific objectives  
To determine how tea flavonoids, specifically rutin, hyperoside, orientin and 
luteolin modulate:  
i. mineral content; 
ii. osteoblast activity, as indicated by ALP  
iii. cell mitochondrial activity;  
iv. cell toxicity;  
v. regulatory protein levels that affect osteoblast signaling: TNFα, interleukin 
6 (IL6), sclerostin (SOST), OPG, and osteopontin (OPN).  
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vi. Study a structure-function relationship, specifically, how a small change in 
structure can lead to changes in mineral deposition, osteoblast activity, cell 
mitochondrial activity, cell toxicity and the regulation of osteoblast 
proteins.   
 
2.2 Hypotheses 
 
Compounds that structurally resemble 17-β estradiol, have been shown to 
influence estrogen receptors through competitive binding. This competitive 
binding leads to biological responses in which genes are either up- or down-
regulated. Furthermore, in estrogen deficient systems, flavonoids such as rutin, 
hyperoside, orientin and luteolin, may act as a substitute for estrogen and 
therefore promote those biological actions. As the majority of epidemiological 
studies involving tea consumption show a positive correlation with BMD, and a 
negative correlation with risk of osteoporosis, the overall hypothesis is that 
individual tea flavonoids rutin, hyperoside, orientin and luteolin will increase 
mineral content, partially by increasing osteoblast activity and favourable 
osteoblast proteins.  
Specific hypotheses:   
i. Rutin, hyperoside, orientin and luteolin will increase mineral content by 
acting as estrogen mimics  
ii. An increase in mineral content will be in part due to an increase in ALP 
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iii. Rutin, hyperoside, orientin and luteolin will improve cellular activity 
iv. Rutin, hyperoside, orientin and luteolin will decrease cell toxicity 
v. Rutin, hyperoside, orientin and luteolin will down regulate osteoblast 
inhibitor SOST, mineral inhibitor OPN and pro-inflammatory markers. 
Rutin, hyperoside, orientin and luteolin will up-regulate OPG, a 
favourable marker for bone formation. 
vi. Changes in rutin, hyperoside, orientin and luteolin structures, such as the 
addition of hydroxyl moieties or glycosylation will change the activity of 
osteoblast cells. As rutin, hyperoside, orientin and luteolin become 
increasingly different from estradiol; rutin, hyperoside, orientin and 
luteolin will have lower activity with respect to those that are closely 
related to estradiol‟s structure.   
 
2.3 Scientific Approach  
 
Multiple outcomes will be measured to comprehensively assess how flavonoids in tea 
modulate key aspects of osteoblast activity. The outcomes include: 
a. Mineral content (primary outcome): Calcium deposits (i.e. bone nodules) 
will be measured using alizarin red staining assay. 
 b. ALP: This enzyme is up-regulated during the process of mineralization and is 
important for providing osteoblasts with the phosphate necessary to produce mineral. 
ALP can be measured using a p-nitrophenyl phosphate assay, where the hydrolysis 
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products (and thus the activity of the enzyme) can be monitored using visible 
spectroscopy. 
c. Cell mitochondrial activity: Wherein a direct relationship exists between 
cellular enzyme activity and cellular viability, cell activity can be monitored by 
quantification of the enzyme: mitochondrial reductase. By adding a coloured tetrazolium 
complex to the cell lysate, a linear relationship between product colour and enzyme 
activity can be established, monitored by visible absorbance spectrometry.   
d. Cell toxicity: Lactate dehydrogenase is measured as a release of cytotoxicity. 
Lactate dehydrogenase is kept within the cytosol, and is released into cellular media 
when the cell dies. Media will be extracted during flavonoid additions to measure the 
toxicity of the flavonoids on Saos2 cells.  
e. Quantification of Regulatory Proteins involved in Osteoblast Activity: An 
extensive panel of proteins will be quantified that are important for osteoblast (and 
indirectly osteoclast) activity. These include: OPG, OPN, SOST, IL6 and TNFα.  
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Abstract 
Osteoporosis is characterized by low bone mineral density that increases an individual’s 
risk to a fragility fracture. Several cross-sectional and prospective studies have shown 
that habitual consumption of tea is associated with a higher bone mineral density in 
women. Tea contains a high concentration and wide-range of flavonoids with differing 
biological activities. Flavonoids are structurally similar to estrogen and therefore may act 
as an estrogen mimic to positively influence bone physiology. The present study analyzed 
two common flavonoids found in tea, rutin and hyperoside, to delineate their effect on 
mineralization in human osteoblast (Saos2) cells. Administration of rutin (≥25µM) and 
hyperoside (≥5µM) resulted in an increase in mineral as determined using the alizarin red 
assay. This increase in mineral was in part due to an increase in alkaline phosphatase 
activity, as determined by the hydrolysis of p-nitrophenyl phosphate. Rutin and 
hyperoside also increased cell mitochondrial activity as measured by the reduction of 3-
(4,5-dimethy-2-lthiazolyl)-2,5-diphenyl-2H-tetrazolium. The expression of osteopontin, 
sclerostin, TNFα and IL6, known stimuli for increasing osteoclast activity and decreasing 
osteoblast activity, were reduced with the addition of rutin or hyperoside. 
Osteoprotegerin, a decoy for RANKL was also suppressed as the result of flavonoid 
supplementation. However, osteoprotegerin is highly expressed in transformed cell lines 
as a decoy for tumor necrosis factor related apoptosis ligand and has been positively 
associated with pro-inflammatory markers. Therefore changes in osteoprotegerin may be 
an artifact of the model chosen. Together, these findings demonstrate that rutin and 
hyperoside positively influence osteoblast activity, resulting in greater formation of 
mineral in Saos2 cells.  
60 
 
 
 
3.1 Introduction 
 Osteoporosis is defined by a low bone mineral density and compromised bone 
structure that leads to a high risk of painful and debilitating fragility fracture [1]. In 
women, the loss of bone mineral and weakening of skeletal sites often occurs most 
rapidly at the time of menopause as ovarian production of endogenous estrogen ceases 
[2]. Resultant fragility fractures are associated with diminished quality of life [3]. 
Furthermore, the risk of re-fracture is elevated if osteoporosis is not managed 
appropriately [4]. Osteoporosis is also a significant burden to the health care system. In 
the United States, over $18 billion is spent on osteoporotic related fractures per year [5].   
Although drug therapies can slow the deterioration of bone tissue and reduce the 
risk of fragility fracture, these strategies represent a treatment approach and can be 
associated with serious adverse effects [6]. Prevention of osteoporosis using dietary 
strategies should also be considered for achievement of peak bone mass by early 
adulthood and maintenance of healthy bone after the growth period [7]. With respect to 
nutrients, calcium and vitamin D have been studied extensively for bone health [8,9] 
while other dietary components such as flavonoids, that are present in large quantities in 
tea, are emerging as potential bioactives that may benefit bone health.  Several 
epidemiological and prospective studies suggest higher BMD is associated with habitual 
tea consumption [10,11,12], and although less studied, some but not all of the few studies 
report lower rates of fracture [13, 14].  Most studies have not categorized the type of tea 
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consumed although black, green, oolong and rooibos tea can differ substantively in their 
composition, and consequently, may have differing biological effects on bone health.  
 
 
 
            
    A           B                             C     D                                                            
Fig. 3.1. The structure of 17β-estradiol (a), quercetin (b), rutin (c), hyperoside (d)  
Rutin is a dissacharide of quercetin and hyperoside is a galactoside of quercetin. The 
structures of quercetin, rutin and hyperoside are similar to the structure of estrogen 
though their multi hydroxyl functional groups and ring systems.   
Flavonoids from tea have been reported to have a wide-range of biological effects 
due to antioxidant [15] and antibacterial properties [16]. Flavonoids may be able to 
mediate these effects due to their structures being similar to 17β-estradiol (Figure 3.1). 
Structural similarity to 17β-estradiol allows flavonoids to bind to the estrogen receptors, 
and ultimately, increase differentiation, proliferation and activity of osteoblasts [17,18].    
Rutin (quercetin-3-O-rutinoside, Figure 3.1) and hyperoside (quercetin-3-O-
galactoside, Figure 3.1) are flavonoids found in green [19], black [19] and rooibos tea 
[20] at some of their highest levels. Rutin and hyperoside can also be found in a variety 
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of other food and beverage sources such as wine [21] and asparagus [22]. Flavonoids 
have the potential to act as strong antioxidants that can protect cells such as osteoblasts 
from damaging free radicals created as the result of inflammatory mediators and cell 
dysfunction. Pro-inflammatory cytokines such as TNFα and IL6 can stimulate 
differentiation and proliferation of osteoclasts and can thereby contribute to higher rates 
of bone resorption [23,24]. Higher production of pro-inflammatory cytokines and overall 
inflammation has been associated with a higher risk of fracture [25,26,27].   
Both rutin and hyperoside are derivatives from quercetin, another flavonoid found 
within tea and a variety of foods [28], however unlike rutin and hyperoside, quercetin 
exists at some of its lowest levels in tea (Figure 3.1). Quercetin has also been shown to 
increase alkaline phosphatase activity (ALP) in osteoblasts in vitro [29], and BMD at the 
lumbar spine and femur in ovariectomized mice [30]. Due to the ability of quercetin to 
increase mineralization in bone cells, we hypothesized that rutin and hyperoside, would 
similarly enhance mineralization as they contain the core structure of quercetin. Rutin 
contains a disaccharide (glucose and rhamnose) on carbon 3 of quercetin, and hyperoside 
has a galactose ring on carbon 3. The presence of a disaccharide or a single galactose ring 
may result in different effects on osteoblast behavior – particularly since the chemical 
structure of hyperoside more closely resembles estradiol than the much larger and 
complex structure of rutin and therefore may increase mineral content at lower 
concentrations. 
While both rutin and hyperoside are present in rooibos tea, only rutin is present in 
plasma at measurable levels after consumption of rooibos tea [31]. However, hyperoside 
has been detected in plasma of rats after consumption of hyperoside tablets [32]. Thus, 
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the bioavailability of these compounds is important to consider, as flavonoids need to be 
absorbed and enter the circulation to induce a biological change. Although hyperoside 
from rooibos tea may not enter plasma at measurable levels, compounds that may 
enhance biological activities in vitro can be enhanced by chemical modification or 
encapsulation to improve bioavailability. Moreover, identifying key moieties on the 
flavonoid structures that enhance activity helps identify bioactives or develop compounds 
that may favorably influence bone cell metabolism.  
 The primary objective of this research was to identify if the addition of rutin and 
hyperoside, flavonoids found in high concentrations in green, black and rooibos tea, 
results in greater mineral content in Saos2 cells as mineral content is an important 
indicator of osteoblast activity. Secondary objectives were to identify if rutin, a 
disaccharide of quercetin, and hyperoside, the galactoside of quercetin, modulate 
osteoblast activity, cell mitochondrial activity, cell toxicity and proteins that modulate 
osteoblast activity (i.e. TNFα, IL6, OPG, SOST, OPN). Because rutin and hyperoside 
have quercetin for their backbone but different glycosides branching from carbon 3, the 
structure-function relationships between these two flavonoids were also investigated to 
provide insight into potential preferential changes in flavonoid structure for enhancing 
mineral content in Saos2 osteosarcoma cells.   
3.2 Methods and Materials 
 Human osteosarcoma cells (Saos2, [33]) were purchased from Cedarlane 
(catalogue # HTB-85, supplier ATCC). HAM-F12, 10X Trypsin, Phosphate buffer saline 
solutions (PBS), fetal bovine serum (FBS) albumin, antibiotic-antimycotic and flasks 
were purchased from Lonza. Rutin trihydrate and 3-(4,5-dimethy-2-lthiazolyl)-2,5-
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diphenyl-2H-tetrazolium bromide was purchased from Alfa Aesar and hyperoside from 
Aktin Chemicals. Epigallocatechin gallate >95%, alizarin red S, paraformaldehyde, 
sodium thiosulfate, p-nitrophenyl phosphate, p-nitrophenol, calcium chloride, HEPES, 
glutamine, dimethylsulfoxide (DMSO) cell culture grade, dexamethasone, β-
glycerophosphate, ascorbic acid and the lactate dehydrogenase activity kit were 
purchased from Sigma-Aldrich.  
 Cells were plated and sustained in HAM F-12 medium supplemented with 10% 
FBS, 0.028M HEPES buffer pH 7.4. 0.0014M CaCl2, 0.002M glutamine and 1% 
antibiotic-antimycotic. Media was changed three times a week and cells were passaged 
weekly. Differentiation occurred by promoting matrix secretion using media 
supplemented with 0.01M dexamethasone and 50µg/ml of ascorbic acid for one week. 
The following day, cell media was supplemented with the matrix media in addition to 
0.01M β-glycerophosphate until day 21. During days 8-21, flavonoids were dissolved in 
DMSO and added at a final volume of 0.1%. Epigallocatechin gallate [34] and DMSO 
were used as a positive control and negative control, respectively. DMSO control was 
compared to cells with no vehicle to ensure no changes in cell morphology and cell death. 
3.2.1 Mineral content 
 Mineral content was quantitatively assessed using alizarin red assay. Cells were 
fixed in 4% paraformaldehyde on day 21 and kept at 4
o
C for 24 hours. Following, cells 
were washed with PBS and replaced with 0.04M alizarin red S stain for 20 minutes on a 
plate shaker at room temperature. Cells were washed with PBS and analyzed using a 
FluorChem imaging system. Extraction required the addition of a 10% cetylpyridinium 
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chloride solution for 1 hour at room temperature. Mineral was quantified by measuring 
visible absorbance spectroscopy at 550nm and compared to controls.  
3.2.2 ALP Activity 
Cells were grown in well plates and lysed with 0.05% Triton X-100 solution 
dissolved in 0.05M Tris-HCl.  Cell lysates were introduced to p-nitrophenyl phosphate 
and p-nitrophenol production was monitored over 5 minutes by absorbance spectroscopy 
at 410nm and normalized by protein concentration using the Bradford assay [34]. Cells 
were tested on days 3, 7 and 10 after the addition of β-glycerophosphate and flavonoid.  
3.2.3 Cell mitochondrial Activity 
Cell activity was assessed by measuring the ability of mitochondrial reductase to 
reduce 3-(4,5-dimethy-2-lthiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). Cells 
were plated, and allowed to adhere over 24 hours. Every 24 hours the flavonoid 
supplemented media was replaced. Cells were harvested after 24, 48 and 72 hours by 
supplementing the media with 5mg/ml MTT dissolved in PBS for 4 hours. Extraction 
required 0.04M HCl-isopropanol and was measured at 570nm with a reference 
measurement at 610nm. Measurements were normalized to cell count, indicated by trypan 
blue.  
3.2.4 Cell Toxicity 
Lactate dehydrogenase (LDH) present in cell media was quantified as a measure 
of cellular death. LDH concentration was determined by an in vitro toxicology assay kit 
from Sigma-Aldrich (Tox7) and normalized to cell count. Cells were allowed to adhere to 
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plates over 24 hours. Media with flavonoid was replaced every 24 hours and cells were 
harvested at 12, 24 and 48 hours.  
3.2.5 Quantification of Regulatory Proteins in Osteoblasts 
Cells were harvested after 3 days into mineralization, after the addition of β-
glycerophosphate and flavonoid. Cell media was analyzed for TNFα, IL6, SOST, OPG 
and OPN using a magnetic ELISA-based commercially-available kit from Millipore 
(HBNMAG-51K).  
3.2.6 Statistics  
Measurements of mineral content and ALP activity consisted of six plates (24 
wells) per flavonoid. Each plate consisted of three wells per treatment, in which each well 
was measured three times by absorbance spectroscopy. MTT and LDH assays were 
measured in 96 well plates using six plates per flavonoid, with each plate containing three 
wells per treatment. Protein measurements were completed using four (75cm
2
) flasks per 
flavonoid. Each flask was measured three times. Measurements are reported as an 
average  standard error mean.  
Data analysis was completed by IBM SPSS Statistics 21 utilizing 1 way-ANOVA 
with vehicle (rutin, hyperoside, or control) as the independent variable (IV). The 
dependent variable (DV) was expressed as per cent DMSO control and was a function of 
mineral content, ALP activity, MTT reduced, and LDH released. For protein 
measurements, the IV was rutin, hyperoside or control. The DV was the protein 
concentration of individual osteoblast markers. If the 1 way-ANOVA was statistically 
significant (p < 0.05), post-HOC analysis allowed for comparison of the IV to determine 
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which groups were statistically different from one another (p < 0.05). Data was checked 
for homogeneity of variance. When homogeneity of variance was not statistically 
different (p > 0.05), post-HOC analysis was completed by Bonferroni t-test. Where 
homogeneity of variance was statistically different across groups (p < 0.05), Games 
Howell t-test was utilized for post-HOC analysis.  
3.3 Results 
 
Fig. 2. Mineral content produced by addition of (a) rutin or (b) hyperoside.  Mineral 
content was measured by alizarin red staining.  † p < 0.05, ‡  p < 0.01, * p < 0.001 
compared to control 
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Figure 3.3. ALP activity with addition of (a) rutin or (b) hyperoside. Activity was 
measured by the rate of hydrolysis of p-nitrophenyl phosphate. † p < 0.05, ‡  p < 0.01, * p 
< 0.001 compared to control within a day. 
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Figure 3.4. Cell mitochondrial activity with addition of (a) rutin or (b) hyperoside.  
Cell mitochondrial activity was measured by reduction of MTT.  † p < 0.05, ‡  p < 0.01, * 
p < 0.001 compared to control within that day   
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Figure 3.5. LDH release by addition of (a) rutin or (b) hyperoside 
LDH activity was measured by the reduction of NAD+ to aid in the conversion of a 
tetrazolium dye to a formazan crystal.  † p < 0.05, ‡  p < 0.01, * p < 0.001 compared to 
control within that day 
 
Table 3.1 Concentrations of regulatory proteins involved in osteoblast activity  
 Protein Concentration (pg/mL) 
 TNFα IL6 PTH OPN OPG SOST 
Control  0.43  0.01 3.24  0.08 17.48  1.00 247.50  
10.71 
1659.25  
107.78 
810.00  
22.15 
Rutin  
(50µM) 
0.20  0.02a* 1.36  
0.09a* 
13.60  1.78 126.21  
10.78* 
431.25   
11.37a‡ 
572.00  
19.07* 
Hyperoside 
(25µM) 
0.25  0.01b* 1.90  
0.06b* 
11.70  0.78† 145.75  
2.75* 
709.25  
25.28b‡ 
542.75  
10.01* 
Significant differences in values, from control, are indicated by,  
 † p < 0.05, ‡  p < 0.01, * p < 0.001  
Significant differences (p < 0.05) between rutin and hyperoside are indicated by 
differences in letters for each column. Data are expressed as mean  SEM 
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3.3.1 Mineral content 
Levels of rutin and hyperoside added to Saos2 cells ranged from 0.01-100µM to 
determine the minimum and maximum effective concentrations that could induce a 
significant increase in mineral content (Figure 3.2). Rutin, when added at levels of 25 
µM, 50 µM and 100 µM resulted in higher mineral content (p < 0.05, p < 0.001, p < 0.01, 
respectively) compared to control. Hyperoside resulted in significantly higher mineral 
content at lower doses (5 µM through 100 µM, p < 0.001) compared to control. DMSO 
control was considered safe as it was not different from cells without vehicle (Data not 
shown). 
3.3.2 ALP activity 
ALP activity was assessed at 3, 7 and 10 days into mineralization to examine at 
when rutin and hyperoside increase ALP activity compared to control (Figure 3.3). Two 
doses in which the flavonoid resulted in higher mineral content were chosen along with 
one dose that did not result in higher mineral content (served as a negative control). Rutin 
(25 µM, 50 µM) resulted in higher ALP activity than control at day 3 (p < 0.01, p < 0.01, 
respectively), and this effect was also observed at day 7 (p < 0.01, p < 0.01, respectively) 
and day 10 (p < 0.01, p < 0.05, respectively). Exposure to hyperoside (5 µM, 25 µM) 
resulted in higher ALP activity than control at day 3 (p < 0.01, p < 0.05, respectively) and 
this persisted at days 7 (p < 0.05, p < 0.05, respectively) and 10 (p < 0.05, p < 0.05, 
respectively).   
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3.3.3 Cell Mitochondrial Activity 
Mitochondrial reductase activity was measured at three time points - 24, 48 and 
72 hours after addition rutin or hyperoside - to assess how single and multiple doses 
change mitochondrial activity (Figure 3.4). These time points were chosen to assess 
immediate and long term effects of flavonoid addition to Saos2 cells. The same doses 
were carried over from ALP activity measurements to measure mitochondrial reductase 
activity. Mitochondrial activity with rutin did not differ from control at any of the doses 
studied (5 µM, 25 µM, 50 µM) within the first 24 hours (p > 0.05). Rutin (25 µM, 50 
µM) significantly increased mitochondrial activity after 48 hours (p < 0.05, p < 0.05, 
respectively) and 72 hours (p < 0.01, p < 0.05, respectively) compared to control. At 24 
hours, hyperoside (5.0 µM, 25.0 µM) increased mitochondrial activity (p < 0.05, p < 
0.05, respectively) compared to control. This heightened mitochondrial activity was 
maintained for 48 hours (p < 0.01, p < 0.05, respectively) and 72 hours (p < 0.01, p < 
0.05, respectively) compared to control.   
3.3.4 Cell Toxicity 
 For consistency, doses of rutin and hyperoside were kept the same as previous 
assays for measuring LDH. Cell toxicity was measured by analyzing LDH released into 
cell media at three different time points (12, 24 and 48 hours) after flavonoid 
supplementation (Figure 3.5).  Time points were chosen to assess immediate and additive 
effects of flavonoid addition on cellular toxicity. After 12 hours of the initial flavonoid 
addition, rutin (25.0 µM 50.0 µM) resulted in lower levels of LDH (p < 0.05, p < 0.05, 
respectively) compared to control. This lower level of LDH was maintained at 24 hours 
(p < 0.05, p < 0.05, respectively) and 48 hours (p < 0.001, p < 0.05, respectively). After 
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12 and 24 hours of supplementation with hyperoside (1.0 µM-25.0 µM), levels of LDH 
did not differ from control. After 48 hours, hyperoside (5.0 µM, 25.0 µM) had 
significantly lower levels of LDH (p < 0.05, p <0.001, respectively) than control. 
3.3.5 Quantification of Regulatory Proteins in Osteoblasts 
For protein measurements, 50 µM of rutin or 25 µM of hyperoside was added to 
cells (Table 3.1). These levels of flavonoids were selected because they had been shown 
to increase mineral content, ALP activity, as well as cell activity without increasing cell 
toxicity.  Rutin and hyperoside resulted in lower levels of IL6 (p < 0.001, p < 0.001), 
TNFα (p < 0.001, p < 0.001), OPG (p < 0.01, p < 0.01), OPN (p < 0.001, p < 0.001) and 
SOST (p < 0.001, p < 0.001) than control. Direct comparison of the effect of rutin (50 
µM) and hyperoside (25 µM) showed that rutin resulted in a greater reduction in TNFα (p 
= 0.035), IL6 (p < 0.002) and OPG (p < 0.001) compared to hyperoside. However, when 
the change in regulatory proteins is normalized to the amount of flavonoid added (per 
mol) using the following equation: (ProteinFlavonoid – ProteinControl)/(molesFlavonoid), 
hyperoside was shown to induce greater changes than rutin (see Table 3.1).  
3.4 Discussion 
Mineral content was enhanced with both rutin (≥25 µM) and hyperoside (≥5 µM) 
in this human cell line. Increases in ALP are identified early into mineralization, in 
addition to higher mitochondrial activity, lower levels of LDH and lower expression of 
TNFα, IL6, SOST, OPN can at least partially explain how rutin and hyperoside enhanced 
mineral content.  Importantly, the addition of rutin (≥25 µM) and hyperoside (≥5 µM) 
was shown to be non-toxic as it resulted in an increase in cell mitochondrial activity and a 
decrease in LDH release. Our finding that rutin (≥25 µM) demonstrated a greater 
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reduction in MTT by 48 hours and lower levels of LDH released by 12 hours, are similar 
to those from a study in mouse bone marrow mesenchymal stem cells which reported 
enhanced mitochondrial activity with the addition of rutin [35].  Likewise, the addition of 
hyperoside (≥5 µM) demonstrated higher levels of MTT and lower levels of LDH in 
comparison to the control, suggesting that both rutin and hyperoside stimulate osteoblast 
activity.   
 Rutin (50 µM) decreased the pro-inflammatory cytokines TNFα and IL6 by 
53.5% and 58%, respectively, and hyperoside (25 µM) demonstrated a similar response, 
with a reduction of TNFα by 42% and IL6 by 41%. Similar to these tea flavonoids, 
previous work demonstrated that the addition of other tea flavonoids, epigallocatechin 
gallate or theaflavin-3,3’-digallate to human gingival fibroblasts attenuated the 
production of IL6 by down regulation of nuclear factor ĸβ [36]. Earlier work has also 
identified that osteoblasts, when placed in the presence of high oxidative stress, 
experienced inhibition of differentiation, marked by a decrease in RUNX2, ALP 
expression and collagen formation [37]. High levels of TNFα have been linked to bone 
loss through increased production of pro-inflammatory cytokines and osteoclast activity 
partnered to lower osteoblast activity [38]. This inhibition of differentiation and 
promotion of apoptosis in osteoblasts has shown to be preventable through pretreatment 
with antioxidants [39]. Moreover, when rats with chronic inflammation were given 0.5% 
green tea polyphenols in their drinking water, the green tea polyphenols were able to 
prevent significant bone loss in part by decreasing the pro-inflammatory cytokines TNFα 
and cyclooxygenase-2, in comparison to control [40].Thus, findings from previous 
studies and the present study suggest that flavonoids commonly present in tea provide a 
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good source of anti-oxidants that may promote mineralization and suppress bone 
resorption.  
 The addition of rutin and hyperoside also resulted in lower levels of OPG. This 
may seem counter-intuitive, as an increase in OPG levels are typically desired when 
administering an agent to prevent osteoporosis [41]. Nonetheless, high levels of OPG are 
also recognized as a marker for cancer. OPG acts as a decoy ligand for tumor necrosis 
factor related apoptosis ligand (TRAIL) [42]. Because TRAIL is important for inducing 
apoptosis primarily in cancerous cells, high levels of OPG are produced by cells such as 
Saos2 cells to prevent apoptosis [42]. Interestingly, previous work has shown that the 
addition of rutin (≥50 µM) to mouse osteoblasts resulted in an increase in OPG [35]. 
Therefore the difference seen between these two studies may be due to differences in 
OPG machinery found within the particular cell line (human osteosarcoma cell line 
versus healthy mouse cell line). Other work has identified that high OPG levels in a 
human osteosarcoma cell line (MG63) are correlated with TNFα [43]. This suggests that 
inflammatory cytokines may aid in tumor proliferation by stimulating the production of 
OPG.  With this knowledge, it is interesting that rutin resulted in significantly lower 
levels of TNFα and IL6 in comparison to hyperoside (similarly to the findings for OPG). 
As the addition of rutin and hyperoside reduced both TNFα and IL6, and previous work 
has shown that levels of TNFα are related to levels of OPG in cancer [43], OPG may 
have decreased as a result of lower levels of TNFα and IL6.  
 Rutin and hyperoside also decreased the release of OPN by 49% and 41%, 
respectively. One study has shown that rutin (≥25 µM) increased in OPN in mouse 
osteoblast cells [35] while another study showed that carnosol from rosemary reduced 
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OPN and IL6 in osteoblasts [44]. OPN is a protein produced by osteoblasts that is 
recognized to aid in bone turnover by anchoring osteoclasts to the surface of bone by 
binding to CD44 on the osteoclast membrane. OPN knock-out mice were shown to have 
reduced osteoclast motility, bone resorption and CD44 expression. Furthermore, these 
knock-out mice also had higher trabecular bone area, less trabecular spacing, higher 
trabecular thickness and mechanical strength [45]. OPN has also been identified to be 
sensitive to changes in redox status of the cell [46], and therefore may also be influenced 
by the presence of antioxidants such as rutin and hyperoside.  
SOST, a marker of osteoblast inhibition, was reduced by the addition of rutin or 
hyperoside to Saos2 cells by 21% and 29%, respectively. SOST is produced by both 
osteoblasts and osteocytes and is an important mediator of osteoblast activity as it can 
inhibit the Wnt pathway. This pathway regulates bone formation, and therefore its 
inhibition is undesirable in individuals experiencing high bone resorption. Stimulation of 
the Wnt pathway allows for the expression of important proteins involved in building the 
matrix and mineral of bone [47]. SOST can bind to the lipoprotein receptor-related 
protein-5 and 6 (LRP5 and LRP6) that subsequently inhibits Wnt from binding to the 
receptors, thereby preventing gene transcription [47]. Previous work has shown that 
mutations in the SOST gene, causing it to be non-functional, are associated with Van 
Buchem disease in which there is excessive accumulation of bone [48]. Therefore, rutin 
and hyperoside may decrease levels of Wnt inhibitors and thus enhance osteoblast 
activity. 
Similar to the favorable effects of rutin observed in the present study, rutin 
administration has been shown to be protective in vivo. While there are no studies in 
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humans that have investigated direct effects of rutin on bone health, a study using 
ovariectomized rats – a well-established model of deterioration of bone tissue due to 
estrogen withdrawal, showed a preservation of BMD in both total and distal femur [49]. 
Higher femur peak load and a reduction in deoxypyridinoline, a marker of bone 
resorption was also observed [49].  These findings are also supported by a study using 
mouse bone marrow stem cells. Rutin (≥ 25µM) enhanced mineral content but a 
significant increase in ALP activity was only observed at concentrations equal to or 
greater than 50 µM [35]. Although mineral was not studied as an outcome, the addition of 
hyperoside (1-100µM) to UMR-106 cells (rat osteosarcoma cell line), has shown a 
significant increase in ALP activity [50] but hyperoside has not been studied using human 
bone cells. 
Assessment of flavonoid structures can help predict bioactivity within various 
biological systems. Hyperoside is able to induce a significant increase in mineral at lower 
concentrations in comparison to rutin (5µM versus 25µM). At carbon 3, hyperoside has a 
galactose ring, and rutin contains a disaccharide. The difference in effective 
concentrations between hyperoside and rutin may be the result of the differences between 
the structures of the two flavonoids. This leads to the question of structure-function 
relationships.  In general, hyperoside more closely resembles estradiol or androgens. In 
contrast, the large structure of rutin is more representative of an antioxidant. With the 
addition of hyperoside and rutin existing at different concentrations, levels of protein 
markers were normalized to flavonoid concentrations on a per mol basis (Table 3.1). 
Normalizing the protein measurements suggests that although the addition of the 
disaccharide results in lower levels of TNFα, IL6, sclerostin, and OPN in comparison to 
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hyperoside, hyperoside is added at half the level. On a per mole basis, hyperoside 
demonstrates a greater reduction in these regulatory proteins compared to rutin. Both 
flavonoids have the potential to act as antioxidants, which would aid in bone formation, 
however, hyperoside resembles estrogen more closely than rutin and therefore may be 
more effective at binding and inducing changes in estrogen pathways at a lower 
concentration.  Binding to estrogen receptors can be further investigated by using 
molecular modeling of rutin and hyperoside in the presence of estrogen receptors. 
 When assessing bioavailability, rutin has been detected in human plasma after 
consuming tea [31] and pure rutin tablets [51] in the low to mid nM range. Consumption 
of rutin by ovariectomized Wistar rats has also translated to doubling of estrogen levels, 
while also significantly increasing levels of prolactin, growth hormone and estrogen 
receptor alpha in plasma and gland tissues [52].  This demonstrates that rutin has the 
potential to influence biological receptors and change gene expression of important 
regulatory hormones and receptors, which are important for regulation of bone turnover.  
In contrast, hyperoside was not detectable in plasma after consumption of tea [31]. 
However, hyperoside has been detected in rat plasma in a dose-dependent manner after 
consumption of hyperoside tablets, but was quickly cleared by the hepatic system [53]. 
Although hyperoside is effective at lower concentrations than rutin, this is also an in vitro 
model and does not involve metabolism after oral ingestion. Therefore hyperoside may be 
a good candidate for encapsulation or chemical enhancement to improve its 
bioavailability in humans.  
Improving bioavailability through encapsulation or chemical modification would 
allow higher levels of flavonoid to reach plasma, and may enhance the ability of a 
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flavonoid to modulate osteoblast activity and mineral formation. Previous work improved 
the oral bioavailability of rutin by 4.5 times in humans when rutin was conjugated to 2-
hydroxy-propyl-β-cyclodextrinin [54]. Therefore to improve bioavailability of 
hyperoside, like previous studies have shown with rutin [54], hyperoside could be 
encapsulated or chemically modified to ensure a more adequate level reaches plasma. In 
addition, bioavailability of flavonoids can be improved when in the presence of other 
bioactives. For example, hypericin has shown to increase its bioavailability by 58% in the 
presence of procyanidin B2 and by 34% in the presence of hyperoside [55]. When 
multiple bioactives are present, interactions can be made to increase solubility and 
stability during absorption. Due to the bioavailability of these flavonoids, to achieve these 
levels of rutin (25 µM) and hyperoside (5 µM) in plasma, supplemental levels above 
those attained through consumption of tea intake would be needed. However, as these 
flavonoids are found in multiple sources of food, and are consumed throughout the day, it 
is hard to know what the plasma levels of these flavonoids would be. Furthermore, the 
higher BMD associated with consumption of tea may be due to the long term 
consumption of multiple flavonoids, leading to potential synergistic and additive effects.  
In summary, rutin and hyperoside enhanced mineral content in Saos2 cells, and 
this was associated with an increase in ALP and cellular activity as well as reduced levels 
of TNFα, IL6, SOST and OPN. Hyperoside’s smaller structure of a single glycoside in 
comparison to rutin’s disaccharide, resulted in a lower effective concentration for 
increasing mineral content and lowering pro-inflammatory cytokines, SOST and OPN. 
Further study is required to determine if increasing bioavailability of these compounds 
benefits bone health, as attaining these levels of rutin (25 µM) and hyperoside (5 µM) 
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would be likely only attained through supplementation.  Findings from this study provide 
a rationale for future research investigating benefits of flavonoid consumption to promote 
bone health. 
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Abstract 
Several epidemiological studies have shown that tea consumption is associated with 
higher bone mineral density in women. Flavonoids in tea are recognized as potential 
estrogen mimics and may positively influence bone metabolism in estrogen deficient 
women. Luteolin and orientin, flavonoids from rooibos tea, are of particular interest as 
rooibos tea contains no caffeine that can be detrimental to bone health. This study 
analyzed changes in mineral content when luteolin or orientin was added to a human 
osteoblast cell line and the potential mechanisms involved. Measurements included 
alkaline phosphatase (ALP) activity, cell mitochondrial activity, toxicity, and changes in 
regulatory proteins involved in osteoblast metabolism. Mineral was significantly elevated 
in Saos2 cells treated with orientin (0.1-1.0µM, 15-100µM) or luteolin (5.0µM) and was 
associated with increased ALP activity and mitochondrial activity, as determined by the 
production of p-nitrophenol and the reduction of 2-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, respectively. Greater mineral content was also associated 
with lower toxicity as determined by lactate dehydrogenase activity and lower expression 
of TNFα, IL6, sclerostin, osteopontin and osteoprotegerin. Rooibos tea contains 
flavonoids that enhance mineral content in human osteoblasts and this is associated with 
higher osteoblast activity and reduced concentrations of TNFα, IL6, osteopontin and 
sclerostin. 
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4.1 Introduction 
Peak bone mass, is attained by early adulthood and may set an individual on a 
trajectory for better bone health. Dietary strategies that promote bone development and 
mineralization are of particular interest as they provide a preventive strategy against 
fragility fractures [1]. It is generally accepted that individuals who achieve a higher peak 
bone mass will be at a lower risk of fragility fracture as they age [2]. Estrogen, 
established as a positive modulator of bone, promotes growth by balancing the activity of 
osteoblasts and osteoclasts [3]. The loss of estrogen is associated with a decrease in 
osteoblast differentiation, activation and proliferation, in addition to an increase in 
osteoclastogenesis, osteoclast activity and inflammation [3]. Pro-inflammatory markers 
also play a vital role in bone turnover, aiding in resorption [4,5] and are significantly 
increased in post-menopausal women [6,7].  
With the increasing age of the general population, preventative measures are 
needed more than ever. It is currently predicted that osteoporosis will cost the United 
States over $25 billion in 2025 due to more than 3 million fragility fractures per year [8].  
While the majority of pharmaceuticals focus on inhibition of osteoclasts to slow bone 
resorption as a treatment for osteoporosis, it is also important to consider preventive 
strategies. Dietary strategies may ensure an individual reaches their peak bone mass and 
support bone health during later stages of life. 
Many population studies that have been conducted throughout the world suggest a 
positive association between habitual consumption of tea and a lower risk of osteoporosis 
[9,10]. As the majority of the benefits are seen in women, estrogen-mediated pathways 
may play an important role in the ability of tea to mediate bone turnover. Tea is rich in 
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flavonoids and the concentration of flavonoids in tea depends on its grade, type and 
oxidation status [11]. Since flavonoids share similar properties to steroids such as 
estrogen due to their structures containing multiple rings and hydroxyl units, flavonoids 
may mediate some of the reported benefits of tea for bone health.  
Luteolin and in particular, orientin (luteolin-8-C-glucoside), are flavonoids that 
are present in their highest concentration in rooibos tea [12]. Rooibos, a South African 
tea, is recognized for its high antioxidant activity [13]. Moreover, the fact that rooibos tea 
does not contain caffeine has added to its increasing popularity in North America [14]. 
Caffeine can be harmful to bone health, as some epidemiological studies have reported a 
positive correlation between higher intakes of caffeine and an increase in risk of fracture 
[15,16]. In addition, higher caffeine intake (>450mg/day, approximately 3.5 cups of 
coffee) has been linked to greater bone loss in individuals who do not achieve adequate 
intakes of calcium in their diet [17].  
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Figure 4.1. Structures of a) 17β-estradiol b) luteolin c) orientin 
Flavonoids luteolin and orientin have similar structures to estrogen. Orientin contains the 
structure of luteolin in its backbone.  
Because luteolin and orientin contain similar structures to estradiol (Figure 4.1) 
and differ only by the addition of a glucose moiety, it was hypothesized that the addition 
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of either of these flavonoids would enhance mineral content in osteoblasts. Thus, the 
objective of this study was to determine if and at what concentration luteolin and orientin 
enhanced mineral content in a human osteoblast cell line. Secondary objectives were to 
determine how other aspects that influence mineral formation were altered – this involved 
measurements of ALP activity, cell mitochondrial activity, cell toxicity, and protein 
concentration of regulatory osteoblast markers including tumor necrosis factor alpha 
(TNFα), IL6, osteoprotegerin (OPG), osteopontin (OPN), and sclerostin (SOST).  
4.2 Methods and Materials  
Saos2 cells were purchased from Cedarlane. Luteolin and 3-(4,5-Dimethy-2-
lthiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased from Alfa 
Aesar. Orientin was purchased from Aktin chemicals. HAM-F12, PBS solution, 
antibiotic-antimycotic, fetal bovine serum (FBS), and trypsin were purchased from 
Lonza. Human Milliplex bone magnetic bead panels for bone metabolism were purchased 
from EMD Millipore. Remaining chemicals including Tox7 kit and epigallocatechin 
gallate (EGCG) >95% were purchased from Sigma-Aldrich. 
Saos2 cells were cultured using HAM F-12 media with 10% FBS, 28mM HEPES 
buffer, 1.4mM CaCl2, 2.0mM glutamine, and 1% antibiotic-antimycotic which was 
adjusted to pH 7.4 using 10.0M NaOH. Stimulation media (media 2) contained 10.0nM 
dexamethasone and 50µg/ml of ascorbic acid and seeded in 24 well plates. On day 8 
media 2 was supplemented with 10mM β-glycerophosphate and treatment (media 3). 
Plated cells were grown until day 21, in which media was changed every other day. 
Flavonoids were dissolved in DMSO and diluted to a final concentration of 0.1%. 
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Controls consisted of cells in regular media, in addition to cells with 0.1% DMSO. On 
day 21 the cells were fixed in 4% paraformaldehyde and kept at 4
o
C. 
4.2.1 Mineral content 
Orientin (0.01µM - 100µM) or luteolin (5µM – 25µM) concentrations were tested 
to determine minimum and maximum effective concentrations. If the flavonoid 
demonstrated potential toxicity, further concentrations were not tested. Mineral was 
quantified using the alizarin red colorimetric assay on day 21. Paraformaldehyde was 
removed from the wells and cells were washed with PBS and dH2O. Cells were stained 
with alizarin red (40mM, pH 4.2) for 20 minutes at room temperature while shaking. 
Cells were then washed and precipitated alizarin red was extracted over 1 hour at room 
temperature using a 10% cetylpyridinium chloride solution in 10mM sodium phosphate 
and quantified with absorbance spectrometry at 550nm [18].   
4.2.2 ALP Activity 
Cells were grown in 24 well-plates and were lysed at days 3, 7 and 10 into 
mineralization to assess ALP activity. Cells were washed and lysed using a 50mM Tris-
HCl solution with 0.05% Triton X-100. Cells were then centrifuged at 1000g, 4
o
C for 
15min. Lysates were introduced to p-nitrophenyl phosphate and monitored for 5 minutes 
in which 0.5M NaOH was used to stop the reaction. The OD was measured at 410nm and 
normalized to protein concentration [19].  
4.2.3 Cell Mitochondrial Activity  
Cell activity was measured by the reduction of MTT by cell mitochondrial 
reductase enzymes. Cells were plated in 96 well plates with media for 24 hours, and then 
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supplemented with flavonoid. Media was replaced every 24 hours and assessed every 24 
hours for 3 days. Examination of cells involved media replacement with 150µl of MTT 
(5mg/ml) in PBS and placed in the incubator at 37
o
C for 4 hours. Crystalized formazan 
was dissolved with 40mM HCl-isopropanol and the OD was measured at 570nm and 
normalized to cell count using trypan blue
 
[20]. 
4.2.4 Cell toxicity 
Cellular toxicity was measured by quantifying the LDH present within the media 
using a Sigma-Aldrich LDH based toxicology kit (Tox7). Cells are seeded in 96 well 
plates and given 24 hours to adhere to plates which were followed by treatment. Media 
was assessed at 12, 24 and 48 hours using kit instructions. OD measurements are 
standardized to cell count using trypan blue.  
4.2.5 Quantification of Regulatory Proteins in Osteoblasts 
Protein expression of TNFα, IL6, SOST, OPG and osteopontin (OPN) were 
quantified using an ELISA based Millipore Magnetic Multiplex kit (HBNMAG-51). 
Cells were seeded and media was harvested at day 3 and 7 following the addition of 
media 3 and used for protein quantification. One concentration of orientin (20µM) and 
luteolin (5.0µM) was studied. The concentration that resulted in a significant increase in 
mineral content, ALP and cell activity, with no increase in cell toxicity was selected.  
4.2.6 Statistics  
Measurements of mineral content, ALP activity, cell activity and toxicity 
consisted of six plates per flavonoid. Each plate consisted of three wells per treatment, 
and each well was measured three times. Protein measurements were completed using 
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four flasks per flavonoid. Each flask was measured three times. Measurements are 
reported as mean  ± SEM.  
Data analysis was completed by IBM SPSS Statistics 21 utilizing 1 way-ANOVA 
with treatment (rutin, hyperoside, control) as the independent variable for all 
measurements except protein. The dependent variable was expressed as a percent of 
control for mineral content, ALP activity, MTT reduced, and LDH released. For protein 
measurements, a 2-way ANOVA was utilized with treatment (orientin, luteolin and 
control) and time as main factors. Level of significance was determined by p < 0.05 and 
post-HOC analysis allowed for comparison between flavonoids (p < 0.05). All data was 
checked for homogeneity of variance. When homogeneity of variance was met (p > 0.05), 
post-HOC analysis was completed by Bonferroni t-test. Where homogeneity of variance 
was statistically different across groups (p < 0.05), post-HOC analysis utilized Games 
Howell t-test.  
4.3. Results  
 
Figure 4.2. Mineral content produced by Saos2 cells with orientin and luteolin  
Mineral was determined using the alizarin red assay. Mineral production as the result of 
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treatment with flavonoid was expressed as per cent control. †  p < 0.05, ‡  p < 0.01, * p < 
0.001 compared to control.  
 
 
Figure 4.3. ALP Activity of Saos2 cells with Orientin and Luteolin 
ALP activity was indicated by hydrolysis of p-nitrophenyl phosphate into p-nitrophenol 
and expressed as per cent control. †  p < 0.05, ‡  p < 0.01, * p < 0.001 compared to 
control within that day.   
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Figure 4.4. Cell activity of Saos2 cells with orientin and luteolin  
Cell activity was measured by the reduction of MTT and expressed as per cent control. †  
p < 0.05, ‡  p < 0.01, * p < 0.001 compared to control within that day. 
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Figure 4.5. LDH released by Saos2 cells with orientin and luteolin 
LDH was measured in cell media by Tox7 kits and expressed as per cent control. †  p < 
0.05, ‡  p < 0.01, * p < 0.001 compared to control within that day.   
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Table 4.1. Concentrations of regulatory proteins involved in osteoblast activity  
 Average Protein Concentration 
 TNFα IL6 OPN OPG SOST 
 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 
Control 0.43 ± 
0.01 
0.20 ± 
0.03a 
3.24 ± 
0.08a 
3.01 ± 
0.13 
247.50 ± 
10.71 
109.00 ± 
1.22 
1659.25 ± 
107.78 
1250.75 
± 32.05 
810.00 ± 
22.15 
1287.25 ± 
29.25 
20.0 µM  
Orientin  
(pg/mL)  
pg/mL/mol
a
 
 
0.09 ± 
0.00* 
-170 
 
0.17 ± 
0.00† 
-15 
 
0.50 ± 
0.02* 
-1,370 
 
2.27 ± 
0.12‡ 
-370 
 
54.89 ± 
8.58* 
-96,300 
 
87.01 ± 
1.94‡ 
-10,995 
 
166.25 ± 
4.70* 
-746,500 
 
789.50 ± 
19.16* 
-230,625 
 
358.00 ± 
10.46* 
-226,000 
 
739.75 ± 
5.98* 
-273,750 
5.0 µM 
Luteolin
 
(pg/mL) 
 
pg/mL/mol
a
 
 
0.13 ± 
0.00* 
-600 
 
0.21 ± 
0.01 
+20 
 
1.25 ± 
0.04* 
-3,980 
 
2.59 ± 
0.09 
-840 
 
137.50 ± 
7.10* 
-219,000 
 
177.00 ± 
12.83* 
+136,000 
 
1096.25b ± 
53.13‡ 
-1,126,000 
 
1172.50 
± 48.33 
-156,500 
 
599.00 ± 
56.73* 
-422,000 
 
1887.00 ± 
55.52* 
+1,199,500 
Data is expressed as mean ± SEM 
Significant differences in from control, are indicated by, † p < 0.05, ‡ p < 0.01, * p < 
0.001 within a column. 
a 
Indicates change in protein expression from control, normalized to the flavonoid 
treatment   
 
4.3.1 Mineral content 
Orientin treatment (0.10µM, 0.50µM, 1.0µM, 15.0µM, 20.0µM, 25.0µM, 
50.0µM, 100µM) resulted in greater mineral content (Figure 4.2) than control (p < 0.001, 
p < 0.01, p < 0.01, p < 0.01, p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively).  
Exposure to luteolin ranged from 5-25µM; concentrations greater than 25µM were not 
studied due to cellular death. Greater mineral content was seen at 5µM luteolin in 
comparison to control (p < 0.05). Luteolin at concentrations of 15µM, 20µM and 25µM 
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had less mineral in comparison to controls (p < 0.05, p < 0.001, p < 0.001, respectively) 
and demonstrated a dose-dependent decrease.  
4.3.2 ALP Activity 
To determine the effect of orientin and luteolin on ALP activity, concentrations 
that had significantly increased mineral content were studied (Figure 4.3).  The addition 
of orientin (0.1µM, 1.0µM, 20.0µM) resulted in higher ALP activity (p < 0.05, p < 0.05, 
p < 0.05, respectively) at day 3, and was maintained at day 7 (p < 0.05, p < 0.01, p < 
0.05, respectively) and day 10 (p < 0.01, p < 0.01, p < 0.05, respectively). 1µM luteolin 
was not different compared to control at days 3 and 7 (p > 0.05) but was higher at day 10 
(p < 0.05). 5µM luteolin demonstrated higher ALP activity at day 3 and 7 (p < 0.05, p < 
0.05, respectively) but not at day 10 (p > 0.05). A higher concentration of luteolin 
(10µM) had lower ALP activity at days 3, 7 and 10 (p < 0.001, p < 0.05, p < 0.05, 
respectively). 
4.3.3 Cell Mitochondrial Activity 
At 48 hours, orientin (0.1µM, 1.0µM, 20µM) resulted in higher levels of MTT 
reduced (p < 0.001, p < 0.05, p < 0.01, respectively) in comparison to control, and this 
was maintained at 72 hours (p < 0.01, p < 0.01, p < 0.05, respectively). After 24 hours of 
the initial flavonoid addition, luteolin (1.0µM, 5.0µM) had higher cell mitochondrial 
activity (p < 0.05, p < 0.01, respectively) in comparison to control, which was maintained 
until 48 hours (p < 0.05, p < 0.05, respectively). At 72 hours, only the 5.0 µM dose of 
luteolin was higher than control (p < 0.05). Mitochondrial activity was lower in 
comparison to control when cells were treated with higher concentrations of luteolin 
(12.5µM, 25µM, 50µM) at 24 hours (p < 0.05, p < 0.01, p < 0.01, respectively), 48 hours 
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(p < 0.01, p < 0.001, p < 0.001, respectively) and 72 hours (p < 0.001, p < 0.001, p < 
0.001, respectively). 
4.3.4 Cell Toxicity 
After 12 and 24 hours of the initial flavonoid addition, orientin (0.1µM, 1.0µM, 
20µM) did not demonstrate different levels of LDH (p > 0.05) in comparison to control 
(Figure 4.5). After 48 hours, orientin (1.0µM and 20µM) resulted in lower LDH release 
(p < 0.01, p < 0.01, respectively). After 12 hours of the initial dose of luteolin (1.0µM, 
5.0µM), there was a decrease in LDH (p < 0.05, p < 0.05, respectively) in comparison to 
control. 24 hours after the initial addition of flavonoid, 1.0µM luteolin had lower levels 
of LDH (p < 0.05) than control. However, the second dose of luteolin (1.0µM, 5.0µM) 
resulted in lower levels of LDH (p < 0.05, p < 0.01, respectively) in comparison to 
control. Higher doses of luteolin (50µM) demonstrated an increase in LDH at 12 hours, 
and this was maintained at 24 hours (p < 0.05, p < 0.01, respectively) in comparison to 
control. After 48 hours, luteolin (25µM and 50µM) demonstrated a dose-dependent 
increase in LDH (p < 0.01, p < 0.01, respectively) relative to the control with 25µM of 
luteolin resulting in lower levels of LDH released from cells than 50µM luteolin (p < 
0.001). 
4.3.5 Quantification of Regulatory Proteins in Osteoblasts 
20µM orientin and 5.0µM luteolin were used to assess concentrations of 
inflammatory and regulatory proteins involved in osteoblast metabolism (Table 4.1). 
20µM orientin was used because it was not found to be statistically different from any of 
the higher doses of orientin (≥25µM) in its ability to produce mineral nor was it toxic to 
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cells. 5.0µM of luteolin was used for these analyses as it was the only concentration of 
luteolin that resulted in greater mineral content compared to control.  
IL6 (p < 0.0001), TNFα (p < 0.0001), OPG (p < 0.0001), OPN (p < 0.0001) and 
SOST (p < 0.0001), all demonstrated a significant interaction between treatment and 
time. There was a main effect of time for IL6 (p < 0.0001), TNFα (p < 0.0001), OPG (p < 
0.0001), OPN (p = 0.004) and SOST (p < 0.0001). There was also a main effect of 
treatment for IL6 (p < 0.0001), TNFα (p < 0.0001), OPG (p < 0.0001), OPN (p < 0.0001) 
and SOST (p < 0.0001).  
At day 3 into mineralization, orientin had lower levels of IL6 (p < 0.001), TNFα 
(p < 0.001), OPG (p < 0.001), SOST (p < 0.001) and OPN (p < 0.01) in comparison to 
control. Luteolin (5µM) had lower levels of IL6 (p < 0.001), TNFα (p < 0.001), OPG (p < 
0.01), SOST (p < 0.001), and OPN (p < 0.001) in comparison to control. At day 7 into 
mineralization, orientin had lower levels of IL6 (p < 0.01), TNFα (p < 0.05), OPG (p < 
0.001), SOST (p < 0.001) and OPN (p < 0.01) while treatment with luteolin resulted in no 
differences in expression of TNFα, IL6, and OPG (p > 0.05) compared to control. 
Luteolin had higher levels of OPN (p < 0.001) and SOST (p < 0.001) in comparison to 
control at day 7 of mineralization.    
When mineral content at 20µM of orientin was compared to 5.0µM luteolin, 
orientin was shown to have higher (p < 0.0001) levels of mineral (143.17% ± 2.27 vs 
112.17% ± 3.63, expressed as per cent relative to control). Therefore, as mineral is the 
primary outcome of this study, and the dose of orientin is higher than the dose of luteolin, 
direct comparisons of protein measurements between the two bioactives may be skewed 
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because of this. To understand which flavonoid resulted in a greater change in protein 
expression in comparison to the control, protein concentration (denoted as C) were 
normalized (see equation 1) by calculating the change in protein concentration from 
control as a function of the flavonoid dose (per mol of flavonoid).  
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Eq. [1] 
This calculation demonstrates that the addition of luteolin by day 3 was shown to 
suppress expression of TNFα, IL6, OPN, OPG and SOST to a greater extent than orientin 
(Table 4.1). By day 7, treatment with orientin was shown to suppress the expression of 
TNFα, OPN, OPG and SOST to a greater extent than luteolin.   
4.4 Discussion 
We have shown that mineral content is enhanced through the addition of orientin 
(0.1-1.0µM, 15-100µM) and luteolin (5.0µM) to Saos2 cells over 21 days. However, the 
lower mineral content with higher doses of luteolin (15-25µM) relative to control 
suggests potentially harmful effects of luteolin at elevated levels. Increased levels of 
mineral were also the result of the ability of orientin and luteolin to increase ALP activity 
and cell mitochondrial activity, reduce cell toxicity, and decrease TNFα, IL6, OPN and 
SOST. Luteolin at concentrations >10µM reduced ALP activity and mitochondrial 
activity while increasing cell toxicity, all of which complemented the lower mineral 
content. 
Orientin has not been previously studied in any bone cell culture systems while 
luteolin has been studied in mouse osteoblasts but not in a human bone cells. In mouse 
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osteoblasts (Mc3t3-E1 cells), 0.1µM luteolin increased ALP activity and collagen 
formation through interactions with estrogen receptors [21].  Furthermore, administration 
of luteolin (0.3-40µM) to murine bone marrow inhibited the process of resorption of 
osteoclasts with an EC50 value of 2.5µM [22]. Thus, combined findings of our study and 
previous studies in mouse bone cells suggest that luteolin may benefit bone turnover by 
increasing osteoblast activity and also limiting the activity of osteoclasts.   
Saos2 cells with orientin (0.1µM – 20µM) or low concentrations of luteolin 
(1.0µM, 5.0µM) had greater mitochondrial activity and lower LDH released. Higher 
doses of luteolin (12.5-50µM) resulted in a decrease in cell activity immediately and this 
effect was sustained. This lower cell activity was accompanied with an increase in LDH 
release, suggesting that high doses of luteolin are toxic to Saos2 cells. Prior research has 
shown that kaempferol, a flavonoid found within tea, when added to rabbit osteoclasts 
would increase apoptosis in a dose dependent manner [23], although, when added to 
human osteoblasts, kaempferol stimulated mineralization and ALP activity, without 
changing cellular activity [24]. But, MTT measurements were only assessed over a single 
dose of flavonoid and therefore changes may only be evident after exposure to multiple 
doses. Similar to findings of the present study, icariine (20µM), a diglucoside of 
kaempferol, was found to increase mineral content and mitochondrial activity in human 
osteoblast cells [25]. 
There was a significant interaction between time and treatment for TNFα, IL6, 
OPG, OPN and SOST, showing that flavonoids have different effects depending on the 
stage of mineralization. At day 3 into mineralization, both orientin (20µM) and luteolin 
(5.0µM) suppressed expression of pro-inflammatory cytokines TNFα and IL6. Orientin 
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reduced TNFα and IL6 by approximately by 79% and 85%. Luteolin decreased TNFα by 
70% and IL6 by 61%. By day 7, TNFα and IL6 remained lower in orientin treated cells, 
whereas cells treated with luteolin had levels of TNFα and IL6 equivalent to control. This 
finding suggests that luteolin may initially have a greater effect than orientin. Yet, 
orientin may demonstrate a cumulative effect and be able to suppress the expression of 
pro-inflammatory markers for longer periods of time. Both luteolin and orientin may act 
as antioxidants and thereby may control reactive oxygen species that are produced as the 
result of cellular stress and damage as they can translate to an increase in pro-
inflammatory markers [26]. Both estrogen and flavonoids are recognized for their ability 
to scavenge reactive oxygen species and limit the production of inflammatory markers 
[27]. Inflammatory markers can increase osteoclastogenesis [28], osteoclast activity [29] 
and inhibit osteoblast differentiation and activity [30,31]. Previous research in which 
rooibos tea was given to seven-week old Wistar rats for 1 month demonstrated an 
increase in superoxide dismutase, an enzyme important for controlling oxidative stress, 
and a decrease in DNA oxidative damage as determined by urine 8-hydroxy-2’-
deoxyguanosine [32]. Work with rat and mouse macrophages has shown that 
pretreatment with luteolin lowers TNFα and IL6 expression when cells were exposed to 
LPS [33]. This suggests that luteolin can down-regulate inflammatory markers in both 
normal and challenged situations, and that the benefits seen within the study presented 
here with suppressing inflammatory cytokines using dietary components could be 
beneficial in limiting osteoclasts and improving osteoblast activity.  
Orientin and luteolin were found to down regulate the production of OPG in 
Saos2 cells early into mineralization. However, by day 7, the concentration of OPG with 
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exposure to orientin remained lower whereas there was no difference in concentration of 
OPG with luteolin compared to control. The lower concentration of OPG early in 
mineralization at day 3 may be due to the model used as the Saos2 system is a 
transformed cell line [34]. Osteosarcomas naturally exhibit extremely high levels of OPG 
due to its ability to inhibit apoptosis in cancer [35,36]. Moreover, previous work has 
shown that OPG levels in cancerous cells are positively linked to levels of pro-
inflammatory cytokines such as TNFα [37].  Therefore changes in OPG expression may 
be the result of changes in pro-inflammatory markers. We observed that both orientin and 
luteolin down-regulated TNFα and IL6 at day 3 into mineralization and thus it follows 
that OPG was also lower. This relationship is demonstrated again at day 7 when 
concentrations of pro-inflammatory markers (IL-6, TNFα) are similar to control with 
luteolin whereas orientin maintains significantly lower levels of TNFα, IL6 and OPG.  
Orientin and luteolin reduced OPN by 78% and 44% and SOST by 56% and 26%, 
in comparison to control at day 3 into mineralization. By day 7, orientin maintained lower 
expression of OPN and SOST by 20% and 43%, respectively. In contrast, luteolin 
treatment by day 7 had higher levels of OPN and SOST (62% and 47%, respectively) in 
comparison to control. OPN functions to increase osteoclast adhesion to bone matrices, 
acts as a chemo-attractant to attract pro-inflammatory cytokines and stimulates 
proliferation and motility of osteoclasts [38]. Once bound to bone, OPN can also prevent 
further production of hydroxyapatite [38]. SOST inhibits bone formation by disallowing 
binding of the glycoprotein Wnt to the frizzled protein receptors and low density 
lipoprotein related receptors 5/6 to stimulate the Wnt conical pathway. If Wnt cannot 
bind to the receptors, β-catenin is tagged for destruction and gene expression of favorable 
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osteoblast proteins is suppressed [39]. Similar to orientin and luteolin, earlier work with a 
citrus flavonoid, hesperetin, has shown that the addition of this flavonoid to rat 
osteoblasts results in lower levels of OPN, while also increasing differentiation of 
osteoblasts via the bone morphogenetic protein pathway [40]. Conversely, the addition of 
ipriflavone, a synthetic isoflavone, to human osteoblasts increased mineral content and 
ALP activity while also increasing OPN mRNA [41]. However it is not currently known 
whether the addition of ipriflavone translated to an increase in OPN protein. Down-
regulation of OPN and SOST by orientin and luteolin, as observed in this study, is a 
beneficial strategy for preventing bone loss as it aids in lowering osteoclast function 
while also increasing the activity of osteoblasts and overall mineral formation. 
Structure-function relationships are important to determine how slight structural 
changes in a flavonoid may result in an increase in osteoblast activity. Orientin is an 8C-
glucoside of luteolin. Our findings suggest that the presence of the glucose affords 
orientin with a wider range of effective concentrations at increasing mineral content 
without increasing cellular toxicity. This change in structure also allows for orientin to 
remain an effective stimulator for osteoblast activity over a longer duration in comparison 
to luteolin. Although the parent compound, luteolin, exhibits an increase in mineral at 
5.0µM, the mineral content is lower than with orientin.  Luteolin also results in lower 
mineral content at high (>10µM) concentrations and an increase in cell toxicity. 
However, when the concentrations of regulatory proteins were normalized to the dose of 
orientin and luteolin used, luteolin has a more potent effect early into mineralization (day 
3). But, orientin maintains lower levels of pro-inflammatory markers, SOST and OPN by 
day 7 while luteolin does not. This highlights the importance of examining time course 
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effects, and may contribute to why orientin successfully produces more mineral in 
comparison to luteolin. This measurement, indicated by difference in protein 
concentration from control, highlights that although luteolin is potentially toxic at higher 
concentrations, the smaller structure of luteolin may bind more effectively to estrogen 
receptors to initiate a change at lower doses in the short term while orientin has longer-
term stability.  
With regards to bioavailability, orientin exists at higher concentrations than 
luteolin (0.02mg/g versus 2.34 mg/g) in unfermented tea and is detectable in plasma after 
consumption of rooibos tea but luteolin was not measured in this study [42]. Luteolin 
glucosides have been detected in human plasma after ingesting extracts containing mono- 
and di-caffeoylquinic acids and caffeic acid combined with luteolin glycosides [43]. Rats 
given tablets of luteolin or luteolin 7-O-β-glucoside had measurable levels of both free 
and metabolite (methyl and sulfate metabolites) forms of luteolin [44]. The 
bioavailability of luteolin has also been enhanced through conjugation to propyleneglycol 
[44]. For these reasons, it may be possible for luteolin to enter plasma with 
supplementation, and have its bioavailability improved upon via chemical modification. 
It is currently unknown how the bioavailability of these flavonoids changes with the 
consumption of food, as ingestion of food may enhance bioavailability through 
synergistic effects with other bioactives. Moreover, both flavonoids are found in various 
food and beverages (such as olives, artichokes, nuts and tea) [45,46,47] and therefore 
may be accumulated in plasma after ingestion of a variety of different foods.  
In conclusion, orientin (0.1µM -1.0µM, 15µM -100µM) and luteolin (5.0µM) 
increase mineral content in Saos2 cells after 21 days in culture. High concentrations of 
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luteolin (>10µM) resulted in reduced mineral content, lower mitochondrial activity and 
higher levels of cellular toxicity. Higher mineral content with addition of orientin (20µM) 
or luteolin (5.0µM) was associated with higher ALP and mitochondrial activity, lower 
toxicity, lower pro-inflammatory cytokines and lower SOST and OPN. The lack of a 
sugar moiety on luteolin demonstrated a better ability to down-regulate levels of OPN, 
SOST, and pro-inflammatory markers in comparison to orientin early into mineralization. 
However, by day 7, only treatment with orientin maintained lower levels of TNFα, IL6, 
SOST and OPN. Higher concentrations of luteolin were also determined to be toxic to 
Saos2 cells. This research suggests that orientin and luteolin, flavonoids that are abundant 
in rooibos tea, have the ability to stimulate osteoblast activity and increase mineralization 
and may thereby be useful for supporting bone health.  
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Chapter 5.0: General Discussion 
 
The addition of rutin (≥25 µM), hyperoside (≥5.0 µM), orientin (≥0.1-1.0, 15.0-
100 µM) and luteolin (5.0 µM) – all flavonoids in rooibos tea - were shown to increase 
mineral content in Saos2 osteoblast-like cells. This increase in mineral content was 
partially due to an increase in ALP activity and cell mitochondrial activity, with no toxic 
effects as determined by release of LDH into cell media. Protein measurements indicated 
that the addition of these rooibos flavonoids resulted in a significant decrease in markers 
that promote bone resorption (SOST, OPN), pro-inflammatory markers (TNFα and IL6). 
Reduction in OPG is believed to be an artifact of the model chosen. Therefore, the 
flavonoids found in rooibos tea may provide a beneficial dietary strategy for prevention 
of osteoporosis in post-menopausal women. Although levels of flavonoids tested in this 
cell model would be likely best achieved through supplementation, there may be potential 
synergistic effects found within tea that promote the higher BMD observed in 
epidemiology studies.  
Previous work with flavonoids has utilized cell systems to predict their ability to 
increase mineral content in vivo. In vitro studies are important for setting the ground work 
to understand how flavonoids and other bioactives interact with osteoblasts and 
osteoclasts at the molecular level. Epigallocatechin gallate (EGCG), a flavonoid found in 
green tea (5µM), has demonstrated an ability to increase mineral content in Saos2 cells as 
the result of an increase in ALP activity, and a decrease in RUNX2 expression [1]. When 
mouse osteoclasts were pretreated with EGCG (20µM), osteoclast formation was 
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significantly inhibited, even in the presence of pro-inflammatory stimulating factors such 
as IL1 and TNFα [2]. When the same level of EGCG (20µM) is added to mouse 
osteoblasts, RANKL nor OPG production changed [2]. However, studies have also 
shown that whole polyphenol extract from green tea induces apoptosis in Saos2 cells 
through activation of caspase-3 and caspase-8 [3].This may due to the addition of 
polyphenols at extremely high concentrations, leading to cell death activated pathways.  
Other studies involving whole tea extract have shown that treatment of normal 
human osteoblasts with black or green tea polyphenol extract resulted in an increase in 
mineral content and ALP activity. Black tea polyphenol extract stimulated ALP activity 
at 5-50 µg/ml, and prevented TNFα suppression of ALP activity. Green tea stimulated 
ALP activity only at low doses (5µg/ml). Therefore both black and green tea polyphenol 
extracts, both were able to increase mineral content and ALP activity [4]. This 
accumulation of work suggested that in vitro, green tea polyphenol extract and black tea 
polyphenol extract were both effective means for inducing mineralization by increasing 
osteoblast activity, while limiting the activity of bone resorption. 
 Work accomplished by in vitro studies is required to be tested in vivo, to ensure 
that the same, desired effect occurs in a living system, without any toxic effects. 
Although we know little about the in vivo effects of rooibos tea, we can learn from in vivo 
studies that have been done using green and black polyphenols.  Previous work in which 
EGCG (3.4mg/kg/day) given to ovariectomized rats for 3 months was shown to be 
effective in vivo as it prevented bone loss as shown by maintaining a higher BMD, 
trabecular thickness, trabecular number, and bone volume [5]. Another study analyzed 
bone outcomes in ovariectomized and sham rats given green tea polyphenols (0.1% or 
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0.5%) for 4 months and found that bone mineral content and BMD were higher in sham 
rats given 0.5% green tea polyphenols in comparison to sham controls. Additionally, in 
the ovariectomized models, BMD was higher in rats given either dose of green tea in 
comparison to control [6]. This suggests that green tea polyphenols could play an active 
role in mitigating bone loss. As green tea polyphenols demonstrate an ability to increase 
favorable bone outcomes such as BMD, trabecular thickness, trabecular number, bone 
volume, ALP activity, tea is seen as a potential dietary strategy for prevention of 
osteoporosis. As rooibos tea contains comparable levels of flavonoids, there is good 
reason to suspect that the beneficial in vitro effects described in this study using rooibos 
tea will translate well into in vivo models.  However, this will still need to be addressed in 
future animal studies. 
But the question remains of how green tea polyphenols, along with flavonoids 
from other tea such as rooibos tea, translates to human studies, as humans have a more 
complex metabolism. Interestingly, a recent intervention involving postmenopausal 
osteopenic women has shown that oral ingestion of a green tea polyphenol supplement 
(500 mg/day) can increase ALP activity as early as 1 month [7]. This study suggests that 
green tea polyphenols can promote positive changes in bone physiology in clinical 
settings. Therefore, potentially through the action of polyphenols, the habitual 
consumption of tea may be a beneficial, proactive method for maintaining healthy, strong 
bones.  
As potential estrogen mimics, flavonoids are currently believed to be the cause of 
these positive changes in post-menopausal models, due to the lack of endogenous 
estrogen. Therefore by acting as an estrogen mimic, these flavonoids can increase gene 
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expression of favorable bone outcomes that positively influence mineral content such as 
ALP activity and RUNX2. Due to the flavonoids having a structural identity that 
resembles estrogen, these flavonoids, like estrogen, can act as an antioxidant. 
Antioxidants help protect osteoblasts and limit the activity of osteoclasts, thereby 
reinforcing a healthy balance for bone turnover.  Rats given 0.5% green tea polyphenols 
for 4 months have demonstrated a 1.3 fold increase in superoxide dismutase, an enzyme 
important for eliminating reactive oxygen species. This study also demonstrated that rats 
given the green tea polyphenols had approximately 1.4 fold decrease in catechol-O-
methyltransferase, an enzyme which deactivates estrogens [8].  High levels of cellular 
stress lead to increased levels of reactive oxygen species, which have been linked to 
significantly lower BMD [8]. Therefore, identification of these molecular pathways, 
could lead to all-natural, dietary options that allow for prevention of osteoporosis.  
 
5.1 Potential pathways for the mechanism of rooibos flavonoids effects 
 
Rutin, hyperoside, orientin and luteolin demonstrate the ability to significantly 
decrease SOST, a Wnt pathway inhibitor (Figure 5.1). The Wnt pathway is important for 
regulation of bone markers such as RUNX2, a transcription factor that controls osteoblast 
differentiation and proliferation; and ALP expression, an enzyme important for 
mineralization. Previous studies have shown that stimulation of the Wnt pathway has 
been associated with an increase in osteoblast differentiation, proliferation and activity; 
while inhibiting the pathway with proteins such as SOST can substantially decrease these 
events [9]. SOST in particular, serves to prevent binding of Wnt to the frizzled receptors 
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and the LRP5/6. If the binding of Wnt does not occur, a protein complex consisting of 
GSK-3 β, APC, and Axin will signal for the degradation of β-catenin, thereby preventing 
β-catenin’s translocation to the nucleus and halting gene transcription. As rutin, 
hyperoside, orientin and luteolin demonstrate an ability to significantly decrease SOST, 
we also see an increase in ALP activity, mineralization, and cellular activity.  
  
Figure 5.1 Changes in Wnt pathway by rooibos flavonoids.  Pink arrows indicate 
changes in SOST and ALP expression by the addition of rooibos flavonoids.  
 At the same time that rooibos flavonoids rutin, hyperoside, orientin and luteolin 
had decreased SOST (aiding in the increase in ALP activity and cell mitochondrial 
activity), these flavonoids also significantly lowered the production of pro-inflammatory 
cytokines TNFα and IL6 (Figure 5.2). Reduction of these pro-inflammatory cytokines can 
aid in mineralization through the reduction of Wnt inhibitors such as SOST. Lower levels 
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of pro-inflammatory cytokines also aids in the reduction of RANKL, important for 
osteoclast activation. Previous work has shown that levels of TNFα and IL6 have been 
negatively linked to osteoblast differentiation and mineralization [10]. Pro-inflammatory 
cytokines are also recognized for their ability to increase osteoclast activity, by increasing 
the production of proteases [11] and tartrate resistant acid phosphatase [12], both of 
which aid in mineral degradation and release. Moreover, high levels of TNFα and IL6 
have been associated with increased levels of osteoclastogenesis [13]. Therefore it is 
beneficial to identify dietary components such as flavonoids from rooibos tea, which 
reduce inflammatory markers and increase mineral content.  
 
Figure 5.2 Changes in bone markers by decreased inflammation via rooibos 
flavonoids. Pink arrows indicate changes in SOST and ALP expression by the addition of 
rooibos flavonoids. 
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5.2 Bioavailability of flavonoids 
Bioavailability of flavonoids is important to induce biological changes through 
dietary means. Both rutin and orientin are found in plasma after consumption of rooibos 
tea, where hyperoside and luteolin was not tested for [14]. Hyperoside has been detected 
in plasma, but is eliminated quickly [15]. Luteolin has been found in plasma, both in its 
free form, and conjugated to glycosides [16]. Moreover, improvements have been 
reported on bioavailability through chemical modification of these flavonoids and 
encapsulation [16, 17].
 
It is likely that the consumption of rutin, hyperoside, orientin and 
luteolin would require supplements to achieve levels that were effective in inducing 
mineralization. However, these flavonoids also may be more readily available when 
consuming multiple flavonoids at once in food matrices, due to possible synergistic 
effects.  
It is also important to recognize that bioavailability of flavonoids, among other 
polyphenols, varies depending on the microbiota that exists within an individual. 
Apigenin is a flavonoid found in many vegetables and beverages including tea and wine. 
When one of apigenin’s glycosides, apigenin-7-glucoside, was incubated with fecal 
microbiota from humans, different metabolites were found in rats, and even more-so in 
comparison to germ-free rats [18]. Moreover, when black tea and red wine polyphenols 
were incubated with different human fecal microbiota samples, there were differences 
across each individual regarding the type of metabolites produced, the levels at which the 
metabolites were produced, and the time at which the metabolites were produced. This is 
believed to be due to the dissimilarity in microbial composition and variation in dietary 
lifestyles [19]. Microbiota largely dictates the distribution, bioavailability and bioactivity 
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of polyphenols such as flavonoids, and therefore plasma levels of flavonoids can fluctuate 
immensely from one individual to another. Thus the microbiota present and the species of 
the model of interest are both important considerations when testing the bioavailability of 
particular dietary components. 
 
5.3 Structure-Function Relationships  
 
Rooibos flavonoids demonstrate an ability to increase mineral content at varying 
concentrations. When considering the flavonoids (rutin, hyperoside and orientin) that 
does not promote cellular death, the larger the molecular compound, the higher the 
minimum effective concentration. Rutin, the largest flavonoid, contains an extra 7 
carbons, 10 hydrogens and 4-5 extra oxygens in comparison to hyperoside and orientin.  
Rutin and hyperoside contain very similar structures, in which both rutin and 
hyperoside contain the quercetin backbone. The difference between rutin and hyperoside 
is the addition of either a disaccharide (rutin) or a galactoside (hyperoside) off of carbon 
3 from the backbone. The benefit of this arrangement is that it allows both compounds to 
have the same side of the backbone to be exposed, and the same side to be crowded by 
their glycosides. When directly comparing these two flavonoids, the smaller flavonoid, 
hyperoside, contains a lower effective concentration. 
 Directly comparing the two quercetin metabolites, rutin and hyperoside, the 
smaller hyperoside demonstrates a more potent effect at lowering pro-inflammatory 
markers TNFα and IL6, when protein levels are normalized to the amount of flavonoid 
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used (per mole basis, see Chapter 3). When comparing all flavonoids that do not 
contribute to cell death, orientin also demonstrates the greatest potential at lowering pro-
inflammatory cytokines. This may be due to the flipped position of orientin’s backbone, 
exposing the ketone and hydroxyl subunits, allowing for more areas of interaction with 
the estrogen receptor. This flipped position, also seems to be beneficial for lowering 
OPN, SOST and OPG, perhaps suggesting that this position of the backbone is more 
effective at binding to receptors due to the increase in potential interactions with the 
newly freed electron acceptors and donators. However, using a flavonoid such as luteolin, 
which is not sterically hindered by the addition of a sugar moiety, is beneficial for 
increasing mineral content at low concentrations, in addition to lowering pro-
inflammatory markers, OPN and SOST – potentially allowing it to more easily interact 
with the estrogen receptor. On the other hand, at slightly higher levels, luteolin prevents 
mineralization and is shown to be toxic to Saos2 cells, potentially through activation of 
cell death cascades. Therefore the addition of a sugar such as glucose is beneficial in that 
it allows for a larger range of effective concentrations at inducing positive influence in 
bone mineralization, but too large of a compound results in a decrease in activity.  
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Table 5.1 Rooibos flavonoids and their corresponding Saos2 regulatory protein measurements  
Flavonoid & 
EC used 
Structure Formula & 
MW (g/mol) 
Min. EC TNFα & 
IL6  (pg/mL) 
OPN 
(pg/mL) 
OPG  
(pg/mL) 
SOST 
(pg/mL) 
Rutin  
(50.0µM) 
OOH
OH O
OH
OH
O
O
O
OH
OH
OH
O
OH
OH
OH
CH3
 
C27H30O16 
610.52 
25.0µM 
 
 
0.20  0.02 
 
1.36  0.09 
126  10.78 431.25  11.37 572.00  19.07 
Hyperoside 
(25.0µM) 
OOH
OH O
OH
OH
O
O
OH
OH
OH
OH
 
C21H20O12 
464.38 
5.0µM 
 
 
0.25  0.01 
 
1.90  0.06 
146.0  2.75 709.25  25.28 542.75  10.01  
Orientin 
(20.0µM) 
O
OH
OH
OH
OH
OOH
OH
OH
OH
O
 
C21H20O11 
448.38 
0.1µM 
 
 
0.09  0.00 
 
0.50  0.02 
54.9  8.58 166.25  4.70 358  10.46 
Luteolin 
(5.0µM) 
O
OH O
OH
OH
OH
 
C15H10O6 
286.24 
5.0µM* 
 
 
0.13  0.00 
 
1.25  0.04 
138.0  7.10 1096  53.13 599  56.73 
Values represented as mean  standard error mean. EC: effective concentration.  
* lower concentrations were not tested due to cellular death 
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5.4 Study strengths and limitations  
 
Strengths: There is strong evidence from epidemiological studies suggesting that habitual 
tea consumption improves BMD and some studies show that habitual consumption of tea 
is linked to a reduced risk of fracture. Tea has high concentrations of estrogen mimics 
known as flavonoids. These flavonoids carry large antioxidant capacity and are believed 
to be producing a biological effect through activation of estrogen receptors. Research 
presented in this study suggests that rooibos flavonoids rutin, orientin, hyperoside and 
luteolin have the potential to modulate osteoblast metabolism to increase mineral content 
in the Saos2 cell culture system.  
The Saos2 cell system is frequently used to study the interactions that occur 
between dietary components and osteoblasts, in an effort to identify bioactives that can 
increase mineral content. Saos2 cells differentiate in a manner which resembles normal 
human osteoblasts [20], while also containing receptors found in normal human 
osteoblasts, such as parathyroid hormone, vitamin D, estrogen, androgen and 
progesterone receptors [21,22,23]. Additionally, the Saos2 cell system offers an 
inexpensive, well-controlled, in vitro model, which may be manipulated using methods 
such as siRNA to assess individual pathways. Saos2 cells are noted for its phenotypic 
instability [24], in which enzyme activity is altered with passage number. Still, this can be 
accounted for by using multiple controls at the same passages at which the experimental 
conditions exist. Due to its ability to endlessly proliferate, this cell system has allowed for 
larger sample sizes, while still using a human cell model. Another benefit to using this 
cell line includes the ability to measure the change in specific osteoblast markers as a 
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result of flavonoid addition, allowing the prediction of potential pathways in which tea 
flavonoids interact with. 
Limitations: There are several limitations to using a cell model, and more so, an 
osteosarcoma cell model. Saos2 cells come from a human osteosarcoma cell line [25], 
and thus it is important to recognize changes in its machinery. For example, 
osteosarcomas have extremely high levels of OPG expressed [26]. OPG is an important 
measure in bone metabolism as it serves as a decoy for RANKL, however in cancer, it 
serves as a decoy for tumor necrosis factor related apoptosis ligand (TRAIL) [27]. 
Therefore it is imperative to reassess the changes in OPG as the result of the addition of a 
flavonoid in a normal human osteoblast model. Furthermore, this cell model represents 
only one half of what happens during bone turnover. Saos2 cells in this study are 
differentiated into osteoblasts, cells that build bone. Therefore it is important to measure 
the effects of these rooibos flavonoids in an osteoclast cell culture. This is necessary to 
ensure that the addition of rooibos flavonoids do not increase osteoclast activity. Lastly, 
as isolated system, cell models do not provide metabolism information that in vivo 
experiments would, and this is important as flavonoids can be modified as they cross the 
small intestine and as they enter plasma. 
 
5.5 Study Knowledge Gaps and Future Research 
 
Flavonoids found in larger concentrations within tea, that are easily quantified 
through analytical techniques are of more interest due to their likelihood of being 
detected in plasma. More work is required to identify how the bioavailability of 
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flavonoids changes with/without consumption of a meal, and how that varies between 
consumption from tea and as a supplement. Furthermore, it would be beneficial to test the 
flavonoids individually as well as produced in a mixture of other flavonoids to examine 
the potential for additive or synergistic effects in a biological system. Timing of the dose 
is important for understanding how often an individual may need to consume tea, or 
ingest supplements for them to increase BMD. Timing investigations should include, 
whether habitual consumption requires the consumption of more than one cup a day, how 
many times a week, and whether supplementation at increased levels of the desired 
flavonoids result in lower consumption requirements.  
As many of these compounds resemble each other’s structures with slight 
differences in position of hydroxyl or sugar components, changes in activity from one 
compound to the next will allow for a better understanding of how chemical structure 
may influence the regulation of important genes in bone physiology. Identification of 
important areas on a specific flavonoid structure may aid in finding other dietary 
components which could positively influence bone health. Moreover, it is important to 
understand that interactions between flavonoids and receptors occur at all areas of the 
body and not just the bone, therefore it is important to also assess the effects that these 
flavonoid concentrations have in other tissues.  
Habitual consumption of tea is suggested to have beneficial effects on bone 
health, primarily in women who are post-menopausal. These potential benefits of habitual 
tea consumption are believed to be an increased BMD but it is largely unknown how tea 
consumption translates to fracture. More data is needed on how tea consumption relates 
to fracture incidence, and more specifically, which type of tea and what levels of 
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consumption are most beneficial. The effects of tea consumption are generally seen 
within women, and lost when consumed by men. This is believed to be due to the fact 
that men produce estrogen through an aromatization of testosterone, and thus do not 
necessarily go through the extreme estrogen deficiency as women do through menopause, 
but instead, have a slow decline in overall testosterone as age progresses. Therefore it 
may be beneficial to compare BMD at different age populations of males who habitually 
consume tea, those in their younger years around peak bone mass, and the elderly to test 
for age specific effects. It is evident that with an increase in tea sales and the mass 
availability of herbs to produce tea that any health benefits tea can provide will have 
world-wide impact and therefore is an important area to investigate when looking for 
dietary strategies to improve bone health.  
6.0 Conclusions  
 
The flavonoids rutin (≥25μM), hyperoside (≥5μM), orientin (0.1μM -1.0μM, 
15μM -100μM) and luteolin (5μM) enhance mineral content in Saos2 cells. This increase 
in mineral is in part due to the flavonoid’s ability to increase ALP activity and cell 
mitochondrial activity in addition to reducing cell toxicity, inflammation (TNFα and 
IL6), SOST and OPN. Luteolin reduced mineral content at concentrations ≥ 15μM. 
Higher levels of luteolin (≥15μM) were linked to significant levels of cell toxicity and a 
reduced level of cell mitochondrial activity.   
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